

THE UNIVERSITY OF WARWICK

Original citation:

Chellan , Prinessa and Sadler, P. J.. (2015) The elements of life and medicines. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, Volume 373 (Number 2037). Article number 20140182.

Permanent WRAP url:

<http://wrap.warwick.ac.uk/67717>

Copyright and reuse:


The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions.

This article is made available under the Creative Commons Attribution 4.0 International license (CC BY 4.0) and may be reused according to the conditions of the license. For more details see: <http://creativecommons.org/licenses/by/4.0/>

A note on versions:

The version presented in WRAP is the published version, or, version of record, and may be cited as it appears here.

For more information, please contact the WRAP Team at: publications@warwick.ac.uk

warwick**publications**wrap

highlight your research

<http://wrap.warwick.ac.uk>

Discussion



CrossMark
click for updates

Cite this article: Chellan P, Sadler PJ. 2015
The elements of life and medicines. *Phil. Trans.
R. Soc. A* **373**: 20140182.
<http://dx.doi.org/10.1098/rsta.2014.0182>

One contribution of 18 to a discussion meeting
issue 'The new chemistry of the elements'.

Subject Areas:

chemical biology

Keywords:

periodic table, essential elements, genetic
codes, inorganic chemistry, coordination
chemistry, metals in medicine

Author for correspondence:

Peter J. Sadler
e-mail: p.j.sadler@warwick.ac.uk

The elements of life and medicines

Prinessa Chellan and Peter J. Sadler

Department of Chemistry, University of Warwick,
Coventry CV4 7AL, UK

Which elements are essential for human life? Here we make an element-by-element journey through the periodic table and attempt to assess whether elements are essential or not, and if they are, whether there is a relevant code for them in the human genome. There are many difficulties such as the human biochemistry of several so-called essential elements is not well understood, and it is not clear how we should classify elements that are involved in the destruction of invading microorganisms, or elements which are essential for microorganisms with which we live in symbiosis. In general, genes do not code for the elements themselves, but for specific chemical species, i.e. for the element, its oxidation state, type and number of coordinated ligands, and the coordination geometry. Today, the biological periodic table is in a position somewhat similar to Mendeleev's chemical periodic table of 1869: there are gaps and we need to do more research to fill them. The periodic table also offers potential for novel therapeutic and diagnostic agents, based on not only essential elements, but also non-essential elements, and on radionuclides. Although the potential for inorganic chemistry in medicine was realized more than 2000 years ago, this area of research is still in its infancy. Future advances in the design of inorganic drugs require more knowledge of their mechanism of action, including target sites and metabolism. Temporal speciation of elements in their biological environments at the atomic level is a major challenge, for which new methods are urgently needed.

1. Introduction

The question 'Which elements are essential for human life?' is frequently asked and seems simple enough

© 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution License <http://creativecommons.org/licenses/by/4.0/>, which permits unrestricted use, provided the original author and source are credited.

to answer. However, the longer you consider it, the more complicated the answer becomes. We know the sequence of the human genome, and surely all essential elements are coded for—but are they? And if so, how? Moreover, an element can be both good and bad for life. For example, there is approximately 80 mg of Cu in the body, and copper, an essential trace element, plays several roles in human physiology, including the development of connective tissue, bone and nerve coverings, but chronic copper toxicity, while rare, can lead to liver damage, and acute copper intoxication can lead to severe gastrointestinal effects [1].

Our answer will also depend on how we define ‘human life’. We live in symbiosis with microorganisms. Approximately 500–1000 species of bacteria live in the human gut [2] and there are more than 10 times as many bacterial cells as human cells in the body [3,4]. If these bacteria have a different requirement for elements than our own cells, do we also call these elements essential for human life?

The human body contains at least 60 detectable chemical elements, however, only about 25 of these elements are believed to participate in the healthy functioning of the human body [5]. The essentiality of additional elements is still in contention, among them arsenic, chromium, boron and lithium, but most studies have been carried out on laboratory mammals (and may or may not be applicable to humans) and the ultra-trace levels of some elements that are present in the body make it difficult to establish their nutritional value [5,6].

Forty to 50 years ago was a period during which nutritionists were carrying out dietary experiments to determine the essentiality of elements, often using rodents. Such experiments were expensive and time-consuming, with the need to purify all components of the diet and to make sure the animals were living under defined conditions. Nutritional researchers included Schwarz, who is not only credited with discovery of the essentiality of selenium [7–10] but also investigated the essentiality of many other elements including Sn [11], Si [12] and Cd [13]. Some of his studies showed that despite being considered non-essential, cadmium, for example, influenced the growth of rats. The growth of weaning rats fed on diets supplemented by Cd at levels normally found in foods showed a small but consistent increase, e.g. 13% growth increase for 0.2 ppm Cd²⁺ sulfate.

Nielsen has discussed the establishment of a recommended daily allowance (RDA) for elements to safeguard against deficiencies. These include not only proven essential elements but also elements thought to be beneficial but for which essentiality has not been proved [14–17]. It can also be argued that nutritional requirements should include consideration of the total health effects of nutrients, not just their roles in preventing deficiency pathology alone. Ultratrace elements with health benefits which were thought to merit specific RDAs include I, Se, Mn, Mo, Cr and B, as well as Co as vitamin B12. Elements with ‘apparent beneficial intake’ included arsenic, fluorine, lithium, nickel, silicon and vanadium [17–20]. It has also been suggested that a healthful diet should provide an appropriate intake of Al, Br, Cd, Ge, Pb, Rb and Sn [18].

Nutritional research on the essentiality of trace elements does not appear to gain such prominence today. Care has to be taken even when extrapolating the requirements of rodents to humans because there are differences in their genome sequences, and therefore protein sequences. The levels of some low molecular weight metabolites (e.g. metal chelating agents such as citrate) may also change.

This paper is not intended to be a comprehensive review, but attempts to highlight current knowledge of essential elements and elements useful in diagnosis and therapy and notable features in their chemistry which relate to their biological activity. We shall find that any code for an essential element that we can recognize is nearly always a code for a specific species of that element, often requiring, for a metal ion, recognition of a particular oxidation state, coordination number, geometry and ligand set.

We travel through the periodic table group by group, starting with group 1 (hydrogen + alkali metals), followed by groups 2, 3–12 (the transition metals, lanthanides and actinides), 13–17 (p-block elements, mostly non-metals and metalloids) and finally group 18, the noble gases. We conclude with a list of elements for which there is good evidence of essentiality for humans.

Perhaps surprisingly, the list is shorter than is believed. The uncertainties in the list will hopefully stimulate much-needed future research in this field.

2. Group 1: hydrogen and the alkali metals

There is no doubt about the essentiality of *hydrogen* ($Z = 1$), the most abundant element in our universe. Hydrogen can be placed in either group 1 or 17. The proton H^+ stands alongside the alkali metal ions, but hydride H^- is also important in the body, not as free ion, but as donated by the reduced coenzyme nicotinic adenine dinucleotide, NAD(P)H.

The control of pH is important in the body. In most body fluids and tissues, the pH is tightly held at pH 7.4 and it is a sign of distress if there is a significant deviation from this value. The control of pH is achieved by buffering, for example, by carbonic acid (H_2CO_3)/bicarbonate in blood and by proteins. In tumour tissues, the pH can drop to 6–7 [21], in lysosomes to 4–5 [22] and in endosomes the pH drops to 5.5 and plays a key role in, for example, the release of Fe^{3+} from its transport protein transferrin [23]. Down the gastrointestinal tract, the pH drops from 6 to 6.5 in the duodenum, to 3.5–7 in the large intestine, to 1–3 in the stomach. The consequences of this for the speciation of some elements are intriguing (e.g. see fluorine).

Although most of natural hydrogen is protium 1H (99.9885%), there is a small amount of the heavier isotope deuterium 2H (0.0115% abundant) in everything we eat and drink. The consequences of kinetic isotope effects for life and the slowing down of biochemical reactions involving the heavier isotopes are interesting and well recognized in the geochemical world [24]. Organisms can incorporate lighter isotopes of transition metals preferentially, which may have consequences for evolution on a long time scale [25]. The pharmaceutical industry uses 2H in multiple ways, including for kinetic isotope effects which can slow down drug metabolism (e.g. a C–D bond is cleaved 6–10 \times more slowly than a C–H bond) [26], for tracing by mass spectrometry, and in medical imaging [26]. Radioactive tritium (3H , half-life 12.3 yr, β^- emitter) is used as a radiotracer. As far as we know, hydrogen gas is not used by man. However, H_2 is an important reductant used by a wide range of bacteria. Hydrogenase enzymes are present in photosynthetic bacteria, nitrogen fixers, cyanobacteria, strict anaerobes, and *Salmonella* and *Escherichia coli* species.

Lithium ($Z = 3$) is not thought to be an essential element, but is present, as Li^+ , in some natural waters, especially ‘spa’ waters (thermal baths) and in some commercial bottled mineral drinking water. There is *ca* 2.4 mg Li in the body.¹ Perhaps, it has beneficial effects at these low levels. In medicine, lithium salts are widely used for treatment of bipolar disorders (BDs). Li^+ is a very small ion (6-coordinate radius 0.76 Å, figure 1) with a high hydration enthalpy (-519 kJ mol^{-1}).

The symptoms of lithium deficiency in humans are believed to manifest primarily as behavioural abnormalities. A link between low lithium intake and altered behaviour and aggressiveness has been reported [29–31]. As a medicine, lithium is best recognized for its anti-manic properties [32]. It is often administered in the form of lithium carbonate, as a psychiatric drug. More than 2 million American adults, or *ca* 1% of the population 18 years or older, suffer from BD [33]. A recent study was conducted on the influence of lithium on the peripheral blood gene expression profiles of patients with BD [34]. For bipolar patients who responded to lithium, the genes which protect against cell death (including Bcl2 and IRS2) were upregulated, while those which promote cell death were downregulated, including the pro-apoptotic genes known as BAD and BAK1 [34]. These results suggest that increased expression of BCL2 and related genes is necessary for the therapeutic effects of lithium.

Lithium is an inhibitor of the enzyme glycogen synthase kinase-3 β (GSK-3 β) which is responsible for the hyper-phosphorylation of the tau protein in Alzheimer’s disease [33]. A link between genetic variations in the gene encoding glutamate decarboxylase-like protein 1 (*GADL1*) and response to lithium maintenance treatment for bipolar I disorder has been found in patients

¹In this article, we have used the data on the abundances of elements in humans given in WebElements: <http://www.webelements.com/> (for a body weight of 80 kg).




Figure 1. Ionic radii and hydration enthalpies of alkali metal ions [27,28]. These key properties have a major influence on their different biological activities.

of Han Chinese descent [35]. The two single-nucleotide polymorphisms (SNPs), rs17026688 and rs17026651, and the *GADL1* variant IVS8 + 48delG are useful markers to predict the response to lithium treatment of patients of Asian descent who have bipolar I disorder.

Sodium ($Z = 11$) and *potassium* ($Z = 19$) are both essential elements that occur at high concentrations in the body (totals of *ca* 112 g and 160 g, respectively). Their crucial roles in cellular homeostasis are well established and they have numerous functions [36]. The biochemistries of Na^+ and K^+ are similar although the ions are distinguishable on the basis of their ionic radii (1.02 versus 1.38 Å for 6-coordination) and hydration enthalpies (-406 versus -322 kJ mol⁻¹), figure 1. There are specific protein pumps for Na^+ and K^+ in cell membranes (Na/K ATPases), which can distinguish between the two ions and maintain plasma Na^+ at an elevated concentration (140 mM) and intracellular Na^+ at a lower concentration (12 mM), while the reverse is true for K^+ (5 versus 140 mM), generating electrical potential gradients responsible for nervous impulses [36]. The process of moving sodium and potassium ions across the cell membrane by the enzyme Na^+/K^+ -ATPase is an active transport process involving the hydrolysis of adenosine triphosphate (ATP) to provide the necessary energy.

Na^+/K^+ -ATPase controls the transport of three Na^+ ions to the outside of the cell and the transport of two K^+ ions to the inside. This unbalanced charge transfer contributes to the separation of charge across the membrane. The sodium–potassium pump is an important contributor to the action potential produced by nerve cells. This pump is called a P-type ion pump because the ATP interactions phosphorylate the transport protein and causes a change in its conformation. For neurons, the Na^+/K^+ -ATPase can be responsible for up to two-thirds of the cell's energy expenditure. Such transport relies on the kinetic lability of bound water molecules (lifetimes *ca* nanoseconds, figure 2) which are rapidly stripped off as the ions pass into the channel.

Potassium also has a natural radioisotope, ^{40}K , with an abundance of 0.012%, a β^- emitter with a half-life of $t_{1/2} = 1.3 \times 10^9$ yr. There is roughly 0.0169 g of ^{40}K present in a typical human body, giving *ca* 266 000 disintegrations per minute, *ca* 4400 disintegrations per second or 4.4 kBq of activity [38].

Rubidium ($Z = 37$) is present in virtually all animal tissues, but is not thought to be essential. In an average adult (80 kg), there is *ca* 37 mg of Rb. Similar to potassium, it is present in large concentrations in muscle tissue, red blood cells and viscera, and is also similar in its biochemistry [39]. Rubidium-82 which decays by electron capture is an attractive radionuclide for positron emission tomography (PET). It can be generated without a cyclotron and has fast serial rest/stress imaging as a consequence of its short half-life (75 s) [40]. It is used clinically for PET myocardial perfusion imaging (MPI) [41]. A protocol has been developed for simultaneous




Figure 2. Rates (and lifetimes) of water exchange on metal ions (adapted from [37]). Note the faster exchange on Ca^{2+} compared with Mg^{2+} and the very slow exchange on some transition metal ions. However, the rate of exchange can also show a marked dependence on the other ligands bound to the metal.

measurement of myocardial blood flow (MBF) and MPI using ^{82}Rb high-count-rate PET [40]. This procedure shows low selectivity for individual patient anatomy or injection site making it a promising tool for obtaining accurate MBF data without loss of image quality [40].

Cesium ($Z = 55$) is a non-essential, trace element in the body. About 1.6 mg of Cs is distributed in muscle, bone and blood [42]. ^{131}Cs (electron capture decay, half-life 9.7 days) has found application in oncology as a treatment for prostate cancer. It is used in brachytherapy, where radioactive seeds are implanted in or near the tumour, exposing it to a high dose of radiation while minimizing radiation exposure of healthy tissues (<http://www.isoray.com/>). A central nervous system (CNS)-active carborane containing cesium has recently been reported to have an antidepressant effect on mice [43] by inhibiting pore formation by the cation-selective purinergic receptor P2X₇R ion channel.

3. Group 2: the alkaline earths

Beryllium ($Z = 4$) is not an essential element (only *ca* 3 μg in the body) and is best known for the high toxicity of many of its compounds—especially for its sensitivity and allergic-type responses. Metal–peptide coordination chemistry appears to play a key role in such immunogenic responses. Be^{2+} is a very small ion (4-coordinate ionic radius 0.41 Å) and consequently highly acidic in water, with a $\text{p}K_{\text{a}}$ of *ca* 3.5 for $[\text{Be}(\text{H}_2\text{O})_4]^{2+}$ and a tendency to form polymeric hydroxide-bridged species.

Allergic attacks are launched by the human immune system when the body is exposed to certain metal ions through skin contacts, inhalation and metal-containing artificial body implants [44]. The magnitude of these allergic reactions can range from simple annoyances to life-threatening systemic illness. Currently, the most widely studied human metal hypersensitivities are to nickel and beryllium. $\alpha\beta$ T cells play a crucial role in these hypersensitivity reactions. Metal ions (plus their ligands) work as haptens, small molecules that can stimulate an immune response only when attached to a large carrier such as a protein, binding to the surface of the major histocompatibility complex (MHC) [45]. This results in a modification of the binding surface of MHC and activates the immune response of T cells. Metal-specific $\alpha\beta$ T-cell receptors (TCRs) are




Figure 4. The polymeric structure of strontium ranelate. Each monomer unit contains two Sr^{2+} ions.

amount of Ba^{2+} may be solubilized by gastric HCl. Barium in Brazil nuts is sometimes a concern. There is a report of a man consuming a single dose of 179 mg Ba from 92 g of Brazil nuts, with more than 91% of the dose absorbed [61].

All isotopes of *radium* ($Z = 88$) are radioactive. There are ultra-trace amounts in our body with no beneficial role. Radium-223 dichloride is an α -emitting pharmaceutical (half-life 11.4 days) approved for treatment of symptomatic bone metastases and castration-resistant prostate cancer (<http://www.xofigo-us.com/index.php> (accessed 10 July 2014)). $^{223}\text{Ra}^{2+}$ is a Ca^{2+} -mimetic that selectively targets bone metastases with short-range high-energy α particles which cause double-strand breaks in DNA as well as greatly localized cytotoxicity, with negligible myelosuppression [76–80]. The activity of ^{223}Ra *in vivo* has prompted evaluation of its efficiency and safety in clinical trials of patients suffering from bone-metastatic prostate cancer [77,79,81–84]. It is an effective candidate for palliation of bone pain.

4. Groups 3–12: the transitions metals

(a) First transition series

Scandium ($Z = 21$) is not an essential element, but its radioisotopes have potential in PET and SPECT imaging, as well as therapy [85]. Both ^{44}Sc ($t_{1/2} = 3.93$ h, 94% β^+ , $E_{\text{max}} 1474$ keV) and ^{47}Sc ($t_{1/2} = 3.35$ days, 100% β^- , $E_{\text{max}} 162$ keV) display appropriate properties for diagnosis or therapy, and, in combination, can be used for theranostic applications. ^{44}Sc is a candidate for PET imaging using radiometalated peptides or other small targeting biomolecules [86]. Preclinical evaluations of DOTA-functionalized biomolecules radiolabelled with ^{44}Sc have demonstrated effectiveness for PET imaging [87]. ^{44}Sc could be a useful radioisotope for clinical nuclear imaging and pre-therapeutic dosimetry of cancer patients prior to treatment with a therapeutic ^{177}Lu -labelled DOTA derivative. ^{47}Sc being a β -emitter has potential as a therapeutic radionuclide and combined with ^{44}Sc would allow use of matching radiopharmaceuticals with the same pharmacokinetics [87].

Titanium ($Z = 22$) is not thought to be essential and is best known in medicine as a light, strong metal in implants, and in anti-cancer complexes, two of which have been on clinical trials. Mice given Ti^{IV} oxalate supplements show positive weight gains and a reduction in tumour development [88]. Beneficial effects on other animals have also been reported [89,90], and interestingly titanium compounds, patented as fodder additives, are claimed to improve weight




Figure 5. Titanium complexes with anti-tumour properties. Titanocene dichloride and budotitane both underwent clinical trials but were abandoned because of instability in aqueous media.

gain in domestic animals [91]. Titanium(IV) complexes were the first class of metal compounds to enter clinical trials after platinum complexes for the treatment of cancer [92]. Budotitane and titanocene dichloride (figure 5) exhibit anti-tumour activity and low toxicity in several cancer cell lines [93]. Unfortunately, clinical trials of these compounds initiated in the 1980s were finally abandoned due their instability in water [92,94]. Since then, other Ti^{IV} complexes have been developed with the aim of overcoming this instability. Among these, titanocene derivatives and titanium salan complexes show promise [95,96]. The titanium complexes Ti-Salan and Ti-Y display contrasting behaviour regarding their reactivities with DNA or albumin, their cellular uptake and intracellular distribution [97]. Ti-Salan shows relatively low binding to biomolecules but increased serum-dependent cellular uptake while Ti-Y shows lower cellular accumulation and high binding to albumin and DNA. Biodistribution data indicate that for Ti-Y transport into nuclei and DNA interactions are crucial whereas mitochondrial targeting is important for Ti-Salan.

Interest in the essentiality of *vanadium* ($Z = 23$) was aroused by the finding about 35 years ago that vanadate present as an impurity in commercial horse skeletal muscle ATP inhibits the enzyme $\text{Na}^+/\text{K}^+-\text{ATPase}$ [98]. Vanadium is thought to be essential for man, but its roles in the body (total of *ca* 2.4 mg) are poorly understood. Vanadium complexes have been on clinical trials recently as antidiabetic agents.




Figure 6. (a,b) Oxovanadium drugs of interest as insulin mimetics.

Genes that code for V are known in some organisms. For example nitrogen-fixing bacteria such as *Azotobacter* [99] contain a Fe_7VS_9 *M*-cluster in vanadium nitrogenase with vanadium coordinated to three sulfides, a histidine-N, and two oxygen functions of homocitrate. Hydrated V^{III} is present in vanadocytes (blood cells) of sea squirts (Ascidiacea) at a concentration of 350 mM! Mushrooms belonging to the genus *Amanita* contain amavadin where V^{IV} is coordinated to two tetradentate *N*-oxymino-2,2'-dipropionate ligands. The oxidovanadium(V) H_2VO core is found in vanadate-dependent haloperoxidases from, *inter alia*, marine algae, coordinated to an active centre histidine-N. These vanadate-dependent haloperoxidases and vanadium nitrogenases remain the only identified vanadium-containing enzymes in nature [99].

In vertebrates, particularly humans, V^{IV} and V^{V} are likely to predominate and the similarity between V^{V} as vanadate and phosphate is likely to be central to its biological effects. Vanadate-dependent haloperoxidases mimic enzymes involved in phosphate metabolism, where vanadate blocks the protein binding domain of phosphate. This competitive binding may account for the insulin-mimetic/insulin-enhancing potential of vanadium compounds. Vanadium complexes can be used to alleviate insufficient insulin response in diabetes mellitus [100]. They may not be able to completely make up for the lack of insulin (as in type 1 diabetes), but can lower dependence on exogenous insulin, or replace other oral hypoglycemic agents, in type 2 diabetes [101]. Both bis(maltolato)oxovanadium(IV) (BMOV) and the ethylmaltol analogue, bis(ethyl-maltolato)oxovanadium(IV) (BEOV) (figure 6), have undergone extensive pre-clinical testing for safety and efficacy [101]. BEOV has advanced to phase II clinical trials. These significant developments in vanadyl insulin mimetics have prompted further research into the biological applicability of vanadium complexes particularly for pharmacological control of cancer and diseases triggered by viruses, bacteria, amoebae and flagellate protozoan parasites [99,102].

In the late 1950s, chromium ($Z = 24$) was proposed as an essential element. However there is no reliable current evidence that chromium is essential. No natural proteins in the body are known to contain Cr and there is no gene that can be said to code for it. Interest in the essentiality of chromium began with the isolation of a chromium complex from extracts of brewers' yeast which enhanced the action of insulin in controlling normal levels of blood sugar [103]. However this complex, so-called 'glucose tolerance factor', thought to contain Cr^{III} and nicotinate and glutathione as ligands, was never fully characterized. Moreover, the glucose tolerance factor itself was subsequently shown not to contain Cr [104].

There is still interest in the possible therapeutic effects of Cr, but its beneficial properties still remain tentative. Today, the US Food and Drug Administration (FDA) recommends a daily adult intake of about $30 \mu\text{g}$ Cr per day, despite its essentiality being in question. Vincent recently concluded that, in fact, Cr has been conclusively shown *not* to have beneficial effects on body mass or composition and should be removed from the list of essential trace elements [105].

Cr^{III} tris(picollinate) is widely marketed as a mineral supplement for weightloss and body-building, although there is concern about possible damage to DNA [104]. Cr^{VI} (chromate) is known to be a genotoxic carcinogen. The toxicity seems likely to arise from redox reactions in cells which generate Cr^{V} 1,2-diolato species (carbohydrates, glycoproteins and sialic acid derivatives)

which can cause oxidative damage to DNA [29]. A recent study of Cr^V complexes with a variety of monosaccharides and the model ligand *cis*-1,2-cyclopentanediol provided evidence of their nuclease activity [29]. The Cr^V complexes can cause oxidative DNA damage without the presence of added reductants or oxidants, supporting the participation of Cr^V 1,2-diolato complexes in the biological activities of both Cr^{VI} and Cr^{III}.

There is no doubt that *manganese* ($Z = 25$, total body Mn *ca* 16 mg) is essential, and that there are genetic codes for a range of Mn enzymes with functions in metabolism, reproduction, the immunological system, regulation of cellular energy and bone and connective tissue growth. Manganese as Mn²⁺ has chemistry similar to Mg²⁺, although unlike the latter it is redox-active, with the +3 state also being readily accessible, as in the enzyme mitochondrial manganese superoxide dismutase. The most abundant Mn-binding protein in the body is glutamine synthetase which plays a prominent role in brain chemistry (in astrocytes).

However, excessively high levels of Mn in the body can be toxic [104]. Industrial Mn toxicity is well recognized, as manganism, a neurodegenerative disorder. Manganism results from overexposure and production of reactive oxygen species and toxic metabolites as well as altered mitochondrial and ATP functions and exhaustion of cellular antioxidant defence mechanisms [106]. Mutations in the Mn exporter gene SLC30A10 are associated with motor impairment and Parkinson's disease-like symptoms.

An intriguing question is how does Mn cross the blood–brain barrier (BBB)? Despite several studies on the mechanism of transport of manganese across the BBB, the exact identity of the carrier is still unclear. Mechanisms using active transport [107] or facilitated diffusion [108,109] have been suggested, as well the high affinity metal transporters of calcium and iron. Manganese may also enter the brain via leak pathways in areas without an intact BBB [110]. Overall, it is likely that more than one transporter is responsible for transport of Mn across the BBB; several of them may work in a cooperative manner to maintain optimal Mn tissue concentrations.

There is about 4.8 g of *iron* ($Z = 26$) in the body and the human genome codes for over 500 Fe-containing proteins [111]. In eukaryotes and prokaryotes, the level of non-haem iron proteins is relatively uniform and their relative number in the proteome decreases in passing from archaea (about 7%), to bacteria (about 4%), to eukaryotes (about 1%) [112]. Several genes are responsible for haem synthesis, haem transport and insertion of haem groups into haem proteins [111,113,114]. Particularly intriguing from an inorganic chemistry standpoint, is the presence of sulfide as a ligand in iron–sulfur proteins [115,116]. H₂S itself is best known as a poison. Fe–S proteins are ubiquitous in cells and play many roles including electron transfer, catalysis and iron regulation (IRP proteins). Sulfide for Fe–S proteins is generated from cysteine by the enzyme cysteine desulfurase. Mutations in proteins involved in Fe–S cluster biogenesis are known to cause at least five distinctive human diseases. Iron–sulfur clusters are also associated with enzymes involved in DNA processing.

The implications of overload or deficiency of iron have been discussed recently [114]. There is a need for new oral iron supplements—the most widely used supplement, ferrous sulfate, was introduced way back in 1832 as a treatment for anaemia. The bioavailability of Fe is affected by plant foods, including phytate (inositol hexaphosphate), polyphenols and tannins [117]. Elevated Fe levels seem to play a role in neurodegeneration [118]. In therapy, the Fe(II) containing compound ferroquine (figure 7), a ferrocene derivative, is currently in phase II clinical trials [119] for treatment of malaria. It is believed to exert its antiplasmodial properties via two mechanisms: interaction with free haem and generation of reactive oxygen species [120]. Ferrocifens, complexes containing ferrocene and tamoxifen fragments show promise as potential drugs for treatment of breast cancer [121]. Superparamagnetic iron oxides composed of nano-sized crystals are used as magnetic resonance imaging (MRI) contrast agents [122] and sodium nitroprusside, Na₂[Fe^{II}(CN)₅NO], which slowly releases nitric oxide, has long been prescribed as a hypertensive agent [123]. Iron overload as in the inherited condition thalassaemia can be treated with iron chelating agents such as deferoxamine (desferrioxamine B, injectable) or more recently deferasirox (oral) (figure 7).




Figure 7. The injectable iron chelator deferoxamine, oral chelator deferasirox and antimalarial drug ferroquine.

There is only *ca* 1.6 mg of *cobalt* ($Z = 27$) in the body, but it plays a vital role in the coenzyme vitamin B12 (cobalamin), which has a recommended daily intake of $2\text{--}3\ \mu\text{g d}^{-1}$. A deficiency of this vitamin results in pernicious anaemia through inactivation of one of two human enzymes for which B12 is the required coenzyme (methionine synthase and methylmalonyl-CoA mutase) [124]. Vitamin B12 can be synthesized only by microorganisms (bacteria and archaea). It contains cobalt tightly bound in a corrin ring and oxidation states +1, +2 and +3 are important in its biological activity. It was the first organometallic complex to be recognized in man and readily forms Co–C bonds (to deoxyadenosyl and methyl groups).

Our genome codes for proteins in the digestive tract that selectively absorb B12 from the diet. Several gene products, including carrier proteins are involved in the absorption and distribution of vitamin B12 [125]. Altered cellular entry, transit or exit of the vitamin can result in deficiency and eventually give rise to haematological and neurological disorders [125]. Under physiological conditions, vitamin B12 is bound to the gastric intrinsic factor (figure 8) and is internalized in the ileum by a highly specific receptor complex composed of cubilin (Cubn) and amnionless (Amn) proteins [124,126]. Following exit of vitamin B12 from the ileum, general cellular uptake from the circulation requires the transcobalamin receptor CD320, whereas kidney reabsorption of cobalamin depends on megalin.

Perhaps surprisingly, there are few cobalt-based drugs. Doxovir, also known as CTC-96, is a Co^{III} bis(2-methylimidazole) acacen derivative which has completed clinical phase I trials for ophthalmic herpetic keratitis and adenoviral conjunctivitis and clinical phase II trials for herpes labialis [127]. We can expect Co^{III} to be reduced to the more labile Co^{II} inside cells.

There is *ca* 8 mg of *nickel* ($Z = 28$) in the body, but it is not clear whether nickel is an essential element for man or not. Nickel allergy is certainly well known—one of the most common allergies in the world. Nickel is certainly an essential element for some bacteria.

For vertebrates, no Ni-dependent enzymes are known [128]; however, in microorganisms several Ni-dependent enzymes have been well characterized. Owing to our symbiotic existence with microbes (of which there are $10\times$ more than human cells in our body), it is possible that Ni is essential for the survival of some of the microbes on which we depend for survival [129]. However Ni can also make some microbes virulent. Nickel is a virulence determinant for the human gastric pathogen *Helicobacter pylori* which possesses two nickel enzymes that are crucial for *in vivo* colonization, [NiFe] hydrogenase (figure 9) and urease, with urease containing 24 nickel ions per active complex [130]. These two nickel trafficking partners in virulence are potential novel therapeutic targets for treatment of *H. pylori* infections which can prevent ulcers from healing [130].

As for beryllium (*vide supra*), metal hypersensitivity is also an immune disorder associated with Ni allergic hyper-reactivity [44]. Approximately 10% of the population suffers from Ni-contact dermatitis. CD4^+ and CD8^+ T cells have been identified as the major effector cells




Figure 8. (a) Structure of vitamin B12, shown as a Co^{III} corrin complex, where $R = 5'$ -deoxyadenosyl Me, OH or CN (cyanocobalamin). (b) Environment around cobalamin (yellow) in the binding site of intrinsic factor, the glycoprotein produced in the stomach and responsible for absorption of vitamin B12 in the small intestine. Water molecules are shown as red spheres. Reprinted with permission from Mathews FS, Gordon MM, Chen Z, Rajashankar KR, Ealick SE, Alpers DH, Sukumar N. 2007 *Proc. Natl Acad. Sci. USA* **104**, 17 311–17 316.




Figure 9. The nickel-containing active site in [NiFe] hydrogenases [128], a virulence factor for microorganisms such as *H. pylori*. These hydrogenases are classified into two categories, the oxidized form (a) which contains a non-protein bridging ligand and the reduced form (b) where the non-protein ligand is absent.

in nickel hypersensitivity [131]. The chemical basis of Ni sensitivity is also becoming better understood. Nickel(II) ions act as haptens that bind to the surface of the MHC and peptide complex, modifying the binding surface of MHC and triggering the immune response of T cells.

Copper ($Z = 29$) is the third most abundant essential transition metal in the body, a total of *ca* 80 mg [132]. In eukaryotes and prokaryotes, the size of the copper proteome approaches 1% of the total proteome [133]. Copper is involved in important biological processes including respiration, angiogenesis and neuromodulation. The structural basis of the activity of copper enzymes and chaperones is now becoming well elucidated [134]. Copper proteins are classified as either type 1, 2 or 3 [135]. Type 1 (blue copper sites) function in single electron transfers [136]. In type 2 copper sites, copper acts as a catalytic centre and binds directly to substrates [135]. Type 3 copper sites are binuclear and involved in the activation and transport of oxygen [135]. Abnormalities in Cu homeostasis are thought to play a role in Alzheimer's, Parkinson's and motor neuron disease [137], but Scheiber *et al.* [134] point out that the full roles of Cu have yet to be clarified.




Figure 10. Zinc plays a role in controlling the mammalian circadian clock. The interfacial tetrahedral Zn binding site between mCRY1 (His473 and Cys414) and mPER2 (Cys1210 and Cys1213) which is involved in the regulation of clock genes. Adapted with permission from [142].

There is about 2.6 g of zinc ($Z = 30$) in the body, and Zn^{2+} is involved in nearly all aspects of molecular and cell biology. Zinc proteins account for about 10% of the human proteome, *ca* 3000 zinc proteins with physiological functions [138]. Zinc plays a role in the structure of proteins as well as in enzymatic catalysis. Its coordination chemistry within proteins has been widely studied [139]. In some cells relatively high concentrations of zinc can be reached in vesicles (millimolar, especially in synaptic vesicles in the brain) where it is stored and undergoes controlled release [140]. With the recognized importance of Zn, Maret has stressed the need for more knowledge of interactions with biomolecules other than proteins if zinc biochemistry is to have a major impact on the diagnosis, prevention and treatment of human disease [140].

The functions of cells of all organisms are influenced by daily and seasonal changes due to the rotation of planets and their orbits around the sun. The predominantly light–dark cycle of the Earth’s rotation gives rise to an endogenous circadian timing system that synchronizes biological functions [141]. Period (PER) proteins are essential to the mammalian circadian clock and recently the crystal structure of a complex comprising the photolyase homology region of mouse CRY1 (mCRY1) and a C-terminal mouse PER2 (mPER2) fragment revealed that zinc is involved in the stabilization of mCRY1–mPER2 interactions *in vivo* [142]. Figure 10 shows the zinc binding site [142].

(b) Second and third transition series

Yttrium ($Z = 39$) is not an essential element, but is used clinically for cancer treatment as the radionuclide ^{90}Y , half-life 2.7 days, a pure β -emitter [143]. It can be delivered to cells as a strongly chelated complex, e.g. (^{90}Y -DOTA-Phe-Tyr)octreotide (SMT487, DOTATOC), figure 11, targeted to somatostatin receptors (SSTRs). ^{86}Y , half-life 14.7 h, which decays by electron capture, can play a complementary role to ^{90}Y for PET imaging of the *in vivo* biodistribution and dosimetry of therapeutic ^{90}Y pharmaceuticals [144].

An average (80 kg) man contains *ca* 4 mg of *zirconium* ($Z = 40$), but Zr has no known biological role. We ingest *ca* 4.2 mg d^{-1} depending on dietary habits [145]. Use of zirconium for biomedical applications is steadily growing [146], e.g. in dental implants [147,148], total knee and hip replacements [149] and middle-ear ossicular chain reconstruction surgery [150]. Like Al^{III} , Zr^{IV} readily forms polymeric oxygen-bridged complexes (e.g. $Zr-O(H)-Zr$ bridges) and is widely used in antiperspirants to coat the skin and prevent escape of (bacterial) body odours [151]. An example is the glycine, chlorido, hydroxido substance aluminium zirconium tetrachlorohydrate gly (as named by the International Nomenclature of Cosmetic Ingredients).




Figure 11. (^{90}Y -DOTA-Phe-Tyr)octreotide [144]. $^{90}\text{Y}^{\text{III}}$ is delivered to cells as a strongly chelated complex conjugated to a peptide vector (as shown here) or antibody where it can be imaged.




Figure 12. Structures of the cofactor MoCo in xanthine oxidase and sulfite oxidase [153].

Niobium ($Z = 41$) is not essential and has yet to be explored widely in therapy. Polyoxometalates containing Nb^{V} are of interest as potential antiviral agents, e.g. heteropolyniobate $[\text{SiW}_9\text{Nb}_3\text{O}_{40}]^{7-}$ [152].

Molybdenum ($Z = 42$) is the only essential trace element in the second and third transition series. Of the *ca* 8 mg in the body, the highest concentrations are in the kidney, liver, small intestine and adrenals [153,154]. The only known chemical form of Mo taken up by cells is the oxyanion molybdate, $[\text{Mo}^{\text{VI}}\text{O}_4]^{2-}$. The human genome codes for four Mo enzymes, in the xanthine oxidoreductase and sulfite oxidase families, in which Mo is bound at the active site by a special molybdenum cofactor (molybdopterin, MoCo, figure 12) [155].

MoCo cofactor deficiency due to gene mutations is known, and can lead to rapid neurodegeneration [156]. In these Mo enzymes, the transfer of oxygen to or from substrates is catalysed by Mo using water as an oxygen atom donor or acceptor. Molybdenum interconverts between two oxidation states, Mo^{IV} and Mo^{VI} . MoCo is synthesized using a highly conserved multi-step biosynthetic pathway. If this biosynthesis is deficient, then a pleiotropic loss of all four human Mo-enzyme activities can occur, and in most cases is accompanied by early childhood death [153].




Figure 13. The ^{99m}Tc complex used for SPECT (γ -ray) imaging of heart muscle. The complex was discovered in the laboratory of Alan Davison at MIT.

Molybdate $[\text{MoO}_4]^{2-}$ is reported to prevent oxidation of lipids and protect antioxidant systems in experimental diabetic rats, and thus may be useful for treatment of diabetic mellitus [157]. Tetrathiomolybdate $[\text{MoS}_4]^{2-}$ is a copper chelator of interest in medicine not only for its ability to lower copper levels [158], but also for treatment of breast cancer and oesophageal carcinoma for which it is in phase II clinical trials.

Technetium ($Z = 43$) is man-made, dating back to 1937. The metastable radioisotope ^{99m}Tc , a γ -emitter with half-life of 6 h, is used in tens of millions of single photon emission computed tomography (SPECT) diagnostic procedures every year. It is readily generated at the bedside from the longer lived isotope ^{99}Mo . More than 50 ^{99m}Tc radiopharmaceuticals are currently in use for imaging and functional studies of various areas of the body, including bone, the brain, thyroid, lungs, myocardium and liver [159]. The ligands play a crucial role in the targeting properties of the complexes, e.g. phosphonate and phosphate complexes for bone. By way of current examples, Cardiolite (^{99m}Tc -sestamibi, figure 13) and Neurite (^{99m}Tc -disicate) have been approved for folate-receptor positive tumours [160]. ^{99m}Tc -MIP-1404 is in clinical phase II trials for prostate cancer imaging [161,162].

Two *ruthenium* ($Z = 44$) complexes are in clinical trials as anti-cancer drugs. They are both octahedral $\text{Ru}(\text{III})$ complexes. The indazole complex KP1019, *trans*- $[\text{RuCl}_4(\text{In})_2]\text{InH}$ (under commercial clinical development as the sodium salt NKP-1339 and IT-139, figure 14) is more cytotoxic to the primary tumour cells than the imidazole complex *trans*- $[\text{RuCl}_4(\text{Im})(\text{DMSO})]\text{ImH}$, NAMI (new anti-tumour metastasis inhibitor)A, which is active against metastases [161,163]. Both have completed phase I clinical trials [164–169]. Ruthenium(III) from these complexes may be delivered to tumour cells by the Fe^{III} transport protein serum transferrin, receptors for which are over-expressed on cancer cells. Once in cells the Ru^{III} may be activated by reduction to Ru^{II} , although Ru^{IV} is also accessible under biological conditions. KP1019 induces apoptosis via the intrinsic mitochondrial pathway. Organometallic Ru^{II} arene complexes also exhibit promising anti-cancer activity [170] and Ru^{III} EDTA complexes have been investigated as NO scavengers for treatment of septic shock [171].

Complexes of the rare precious metal *rhodium* ($Z = 45$) are currently the focus of several studies as anti-tumour, antiparasitic and antiviral agents [172–175]. The radionuclide ^{105}Rh (β^- emitter, half-life 35.4 h) is useful medically. For example, ^{105}Rh -EDTMP is a promising therapeutic agent for




Figure 14. Some Ru^{III} and Ru^{II} anti-cancer complexes. Both NAMI-A and KP1019 (as the sodium salt NKP-1339 and IT-139) are in clinical trials.

treatment of pain due to bone metastases, displaying rapid blood clearance and selective uptake into bone [176].

As yet, *palladium* ($Z = 46$) has found only limited uses in medicine. A Pd-bacteriopheophorbide (TOOKAD) is a photoactivatable compound that is currently being evaluated in phase III clinical trials for localized prostate cancer and in phase I/II trials for treatment of small renal tumour targets [177,178]. It can be activated by long wavelength light (approx. 763 nm) allowing deep tissue penetration and displaying rapid clearance from the bloodstream [177].

The radionuclide ^{103}Pd (half-life 17 days, decays by electron capture) was introduced for brachytherapy in 1989 [179]. A study spanning 11 years found that utilization of ^{103}Pd for plaque radiotherapy of choroidal melanoma resulted in improved visual function when compared to the use of ^{125}I [180]. Currently, ^{103}Pd is in phase III clinical trials for treatment of early stage prostate cancer [181,182].

Silver ($Z = 47$) is best known in daily life for its potent antimicrobial properties. As far back as the eighteenth century silver was used for wound management [183]. In the form of silver nitrate, it was employed to treat ulcers [184] and silver ions were identified as antimicrobial in the nineteenth century. Colloidal silver was approved for wound management by the FDA in the 1920s [185]. In 1968, silver nitrate was combined with a sulfonamide antibiotic to produce silver sulfadiazine, a topical antibacterial agent prescribed for burn management that is still in use [186,187]. Silver-containing wound dressings are often used in lieu of prescription antibiotics due to the emergence and rise in (organic) antibiotic-resistant bacteria [188]. Acticoat absorbant is a silver-releasing dressing in phase IV clinical trial for the prevention of lower extremity revascularization wound complications [189]. Silver nanoparticles are also being evaluated as antiviral agents [190] and for drug delivery [191].

There is *cadmium* ($Z = 48$) in the body (*ca* 56 mg) and although it is possible that it is essential at very low doses (see Introduction), it is usually considered to be toxic. Cadmium(II) has a high affinity for sulfur ligands, e.g. in the protein metallothionein, where it can displace natural Zn^{2+} from $\text{Zn}(\text{Cys})_4$ sites [192], which may have implications for the cellular toxicity of Cd [193]. Intriguingly, the cadmium-dependent carbonic anhydrase in the marine diatom *T. weissflogii* [194] uses Cd as its natural metal cofactor when only low concentrations of Zn are available.

Hafnium ($Z = 49$) has no known biological role. There is interest in 50 nm diameter spheres of hafnium oxide functionalized with a negative surface (NBTXR3) [195,196]. NBTXR3 nanoparticles are taken up efficiently by tumour cells and can enhance the effects of radiation therapy. They are in phase I clinical development for advanced soft tissue sarcomas and head and neck cancer [197].

Tantalum ($Z = 73$) is best known for its inertness and hardness as a metal and is commonly used in implants and bone repair [198,199]. The porosity of Ta provides a scaffold for bone ingrowth and mechanical attachment [200–202].

Tungsten ($Z = 74$) is not essential for man. It is most commonly encountered in biological systems as W^{VI} in tungstate $[WO_4]^{2-}$ [203]. Sodium tungstate has antidiabetic properties. $[WO_4]^{2-}$ can normalize glycemia when administered orally in several types 1 and 2 diabetic animal models [204–207]. In primary cultured hepatocytes sodium tungstate behaves in a similar manner to insulin, increasing glycogen synthesis and accumulation [208], and induces a transient strong activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), in the same way as insulin. Some oxidoreductase enzymes in bacteria employ W in a similar manner to Mo [209,210]. Polyoxotungstates are also being studied for a range of other medicinal applications including antiviral [211], antibacterial [212], anti-cancer [213] and for the treatment of Alzheimer's disease [192].

Radioisotopes of *rhenium* ($Z = 75$), ^{188}Re (half-life 16.9 d, β^- emitter) and ^{186}Re (half-life 3.8 days, decays by electron capture and β^- emission), are used to treat cancer. Colloidal sulfur particles labelled with ^{186}Re are used in radiation synovectomy in the treatment of rheumatoid arthritis [214] and ^{188}Re -1,1-hydroxyethylidenediphosphonate (^{188}Re -HEDP) for bone pain palliation in patients suffering prostate cancer [215]. ^{188}Re P2045 is currently in phase I/II clinical trials for treatment of small cell lung cancer and other advanced neuroendocrine carcinomas [216]. P2045 is an 11-amino acid somatostatin analogue peptide which has a high affinity for the SSTR [217]. The SSTR is expressed in both small and non-small cell lung cancers [218,219] as well as on peritumoural blood vessels in numerous malignancies [220,221].

The only current medical use of the precious metal *osmium* ($Z = 76$) is injections of aqueous osmium tetroxide (OsO_4) to destroy diseased tissue in chronically inflamed arthritic joints [222,223]. OsO_4 acts as a superoxide dismutase mimic, catalysing the dismutation of the superoxide which is a primary inflammatory species [224]. Organo-osmium arene complexes show promise as anti-cancer drugs [225].

Iridium ($Z = 77$) is used clinically for cancer brachytherapy as the radionuclide ^{192}Ir (half-life 73.8 days, β^- emitter), and is currently in phase III evaluation for stage B2 and C prostatic carcinoma [226] and in phase I/II trials of a GAMMA-Iridium-192 catheter for coronary artery disease [227]. Iridium(III) complexes can act as inhibitors of protein kinases and protein–protein interactions [228], and photoactive polypyridyl iridium complexes are potential candidates for photodynamic therapy [229–231]. Organoiridium(III) cyclopentadienyl complexes show promise as anti-cancer agents (figure 15). Some appear to catalyse the conversion of NADH to NAD^+ in cells by transfer of hydride to Ir^{III} [231].

Currently the most widely used drugs for cancer chemotherapy are *platinum* ($Z = 78$) complexes, now components of approaching 50% of all treatments. The initial drug cisplatin *cis*- $[\text{PtCl}_2(\text{NH}_3)_2]$ (figure 16) originated from the laboratory of Barnett Rosenberg at Michigan State University in the 1960s, and has now been joined by its analogues carboplatin *cis*- $[\text{Pt}(1,1\text{-dicarboxycyclobutane})(\text{NH}_3)_2]$ and oxaliplatin $[\text{Pt}(1R,2R\text{-}1,2\text{-diaminocyclohexane})(\text{oxalate})]$ which have been approved worldwide. Nedaplatin, lobaplatin and heptaplatin are approved for use in Japan, China and South Korea [233]. Lipoplatin, formed from cisplatin and liposomes of dipaamitoyl phosphatidyl, soy phosphatidyl choline (SPC-3), cholesterol and methoxypolyethylene glycol-distearoyl phosphatidylethanolamine (mPEG2000-DSPE) [234] has completed phase III clinical trials [234,235]. The highly positively charged Pt_2 and Pt_3 complexes of Farrell form an interesting new class of potent agents [236].

There is interest in nanoparticle formulations of platinum drugs that can include built-in targeting vectors [237,238]. The primary cellular target of platinum drugs is DNA [239], but there is increasing interest in the role of proteins, especially the copper transporter CTR1 [240]. Platinum(IV) complexes with their low-spin d^6 configuration are of interest as pro-drugs which can be reduced *in vivo* either chemically (e.g. by thiols or ascorbate) or by irradiation with light to active Pt^{II} species [238,241,242]. Polymer nanoparticles that contain a covalently linked Pt^{IV}




Figure 15. Structure–activity relationships for half-sandwich Ir^{III} cyclopentadienyl anti-cancer complexes towards A2780 human ovarian cancer cells [231]. Reprinted with permission from Liu Z, Sadler PJ. 2014 *Acc. Chem. Res.* **47**, 1174–1185. Copyright © 2014 American Chemical Society.




Figure 16. Platinum anti-cancer complexes which have been approved for clinical use [232].

polymer conjugate are stable during circulation, enter target cells by endocytosis, and rapid intracellular drug release is triggered by the acidic environment [243].

The use of *gold* ($Z = 79$) in medicine (chrysotherapy) dates back to ancient times, when Chinese and Indian practitioners used powdered gold to treat many illnesses including arthritis [244]. The modern application of gold compounds in medicine was prompted by Robert Koch's discovery of the tuberculostatic properties of gold cyanide solutions [244,245], and by the (mistaken) belief by the French physician Forrester that tuberculosis and rheumatoid arthritis are linked. From the 1930s, gold(I) complexes including $\text{Na}_3[\text{Au}(\text{S}_2\text{O}_3)_2]$ (Sanocrysin), aurothiomalate (Myocrisin), and aurothioglucose (Solganol) have been administered by intramuscular injection, and in 1986 these were joined by the oral drug auranofin (figure 17), (triethylphosphine)gold(I)tetraacetylthioglucose (Ridaura) [244,245]. Aurothiomalate and aurothioglucose are polymeric with thiolate S atoms bridging Au(I) ions giving linear S–Au–S coordination. The target sites for gold drugs are likely to be proteins, especially cysteine thiolate sulfur and selenium in selenocysteine, as in mitochondrial thioredoxin reductase (TrxR) [244].

There is interest in using auranofin for other types of therapy such as anti-HIV, chronic lymphatic leukaemia and squamous cell lung cancer [245,246]. The potential of gold nanoparticles (AuNPs) is now being explored with many examples of AuNPs conjugated to peptides or




Figure 17. The antibacterial Hg^{II} agent thiomersal, oral antiarthritic Au^I drug auranofin and polymeric structure of the injectable antiarthritic Au^I drug aurothiomalate (Myocrisin).

antibodies being studied as gene-regulating agents, drug carriers, photothermal therapy agents and imaging agents [247–250]. Recently, the activity of auranofin against amoebic dysentery has been discovered [251].

These days, the use of *mercury* ($Z = 80$) in therapeutics is declining. In earlier times, Hg was used to treat syphilis, as an antibiotic and was the active ingredient in diuretics, antiseptics, analgesics and laxatives [252]. Dental amalgam fillings are about 40% Hg by weight. Thiomersal, an organomercury compound, has antiseptic and antifungal properties. It was mainly used as an antimicrobial preservative in vaccines in the mid-twentieth century to prevent adverse effects such as *Staphylococcus* infection [253]. It did not reduce the potency of the vaccines [254]. There is a fear that thiomersal could trigger or cause autism in children, but this has yet to be proven [255]. Some vaccines not recommended for young children do still contain thiomersal such as those prescribed for diphtheria and tetanus (http://www.who.int/vaccine_safety/committee/topics/thiomersal/questions/en/ (accessed 11 August 2014)), and the World Health Organisation has deemed that there is no solid evidence of toxicity from thiomersal (<http://www.who.int/biologicals/areas/vaccines/thiomersal/en/> (accessed 11 August 2014)).

(c) The lanthanide and actinide elements (group 3+)

Lanthanum ($Z = 57$) in the form of La_2CO_3 (Fosrenol) was approved in 2004 for treatment of hyperphosphatemia [256], an electrolyte imbalance that results in elevated levels of phosphate in the blood. Hyperphosphatemia is more severe in patients suffering from renal failure as a result of increased FGF-23 levels, secondary hyperparathyroidism and enhanced progressive vascular calcification [257]. Fosrenol acts as a phosphate binder, reducing absorption of phosphate through the formation of insoluble lanthanum phosphate complexes which can then pass through the gastrointestinal tract unabsorbed [258]. *In vitro* experiments show that La^{3+} binds to phosphate in the pH range of 3–7. Approximately 97% of available phosphate is bound between pH 3 and 5 and 67% at pH 7 in simulated gastric fluid with La^{3+} in a twofold molar excess over phosphate (<http://www.rxlist.com/fosrenol-drug/clinical-pharmacology.html> (accessed 11 August 2014)).

Interestingly, lanthanum, cerium and praseodymium compounds have been used as feed additives for animal production in China for more than 50 years [259]. It is well documented that small amounts of these additives can lead to greater weight gain in pigs, cattle, sheep and chickens [259,260].

Cerium ($Z = 58$) has bacteriostatic properties; it is effective in the form cerium nitrate against a wide range of bacteria in a pH-dependent manner. In *Escherichia coli*, Ce is readily taken up into the cell cytoplasm, in contrast to mammalian cells, and there is clear inhibition of cellular

respiration, glucose metabolism and oxygen uptake [261]. A Ce^{3+} nitrate–silver sulfadiazine formulation (also known as Flammacerium) has been used for treatment of burn wounds [262]. Cerium nitrate is believed to exert a protecting effect against postburn immunosuppression caused by a high molecular weight (3 MDa) lipid protein complex [262–265].

The *samarium* ($Z = 62$) radionuclide ^{153}Sm (β^- decay, half-life 1.9 days) is one of the more extensively used radiopharmaceuticals and as ^{153}Sm -ethylenediaminetetramethylphosphonic acid (^{153}Sm -EDTMP) stabilizes pain in patients suffering from osteoblastic metastatic bone lesions [266]. ^{153}Sm -EDTMP is well tolerated by the body at doses of 37 MBq kg^{-1} body weight [266], shows an affinity for skeletal tissue and localizes in the skeleton and areas of increased bone turnover [267–269]. Subsequent to intravenous dosing, *ca* 50–60% of this complex is concentrated in bone within 2–3 h of administration [270], the highest amount reported for bone-seeking radiopharmaceuticals [271]. It has a small range of emission in bone (1.7 mm), thus limiting exposure of bone marrow and adjacent tissues to radiation [269,272]. ^{153}Sm -EDTMP is currently in phase II clinical trials for treatment of high-risk osteosarcoma [273] and breast cancer metastatic to bone only [274] as well as phase I/II trials in combination with zoledronic acid or pamidronate for patients suffering from relapsed or refractory multiple myeloma and bone pain [275].

There are only a few examples of the use of *europium* ($Z = 63$) in medicine. It has potential as a PARACEST MRI contrast agent. Paramagnetic metal complexes are often employed as exogenous contrast agents to reduce the relaxation time of water protons, thus enhancing tissue contrast in MRI [276]. A europium(III) DOTA-tetraamide complex can act as an MRI sensor of singlet oxygen ($^1\text{O}_2$) [276]. This complex forms an endoperoxide derivative upon rapid reaction with $^1\text{O}_2$ resulting in a *ca* 3 ppm shift of the Eu^{3+} -bound water peak through chemical exchange saturation transfer. This could prove useful for detection of singlet oxygen in cells during photodynamic therapy. Luminescent Eu^{3+} -doped nanoporous silica nanospheres functionalized with folate *N*-hydroxysuccinimidyl ester molecules have been designed to enhance the imaging of cancer cells [277].

Millions of doses of *gadolinium* ($Z = 64$) are now administered every year as contrast agents for MRI. Gadolinium(III) with its seven unpaired electrons and slow electronic relaxation time is effective for relaxing H_2O protons which can give rise to contrast in MR images. Thanks to the high thermodynamic and kinetic stability of chelated complexes such as $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$ (figure 18, approved for clinical use in 1988 as gadopentetate dimeglumine, Magnevist) [278] and $[\text{Gd}(\text{DOTA})(\text{H}_2\text{O})]^-$ (Dotarem), they can be safely injected in gram quantities. The large Gd^{III} ion (radius *ca* 1.2 Å) can accommodate eight coordinating atoms from the chelating ligand plus a water ligand which exchanges rapidly with bulk water. There is concern about possible side-effects arising from any release of $\text{Gd}(\text{III})$ (e.g. displacement by $\text{Ca}(\text{II})$) in the body, especially for less stable contrast agents. Currently, phase IV clinical trials are underway to evaluate Gd retention in the bones of patients with impaired renal function [279].

The radioisotope of *holmium* ($Z = 67$) ^{166}Ho is used as a substitute for ^{188}Re (β^- decay, half-life 19.4 h) due to its suitable characteristics for internal radiation therapy. ^{166}Ho has a half-life of 26.8 h, and emits high β -energy and low γ -energy which can be easily detected by gamma cameras [280]. Chitosan functionalized with ^{166}Ho is being used as a cancer radiopharmaceutical in Korea [281]. Poly(L-lactic acid) microspheres loaded with ^{166}Ho -acetylacetonate are being used for intra-arterial radioembolization in patients with unresectable liver malignancies [282,283]. These microspheres have already completed phase I trials for treatment of liver metastases [284] and will begin phase II trials in unresectable liver metastases soon [285].

The *ytterbium* ($Z = 70$) radioisotope ^{175}Yb also displays favourable decay characteristics for therapeutic applications, with a half-life of 4.2 days and a maximum β -energy of 480 keV [286]. ^{175}Yb -labelled polyaminophosphonates have been evaluated for palliative therapy of bone metastases [287]. These complexes have high bone uptake with a minimal uptake in soft tissue and rapid blood clearance. Ytterbium-169 is a γ -emitter with a much longer half-life of 32 days, and is being explored as a potential therapeutic for intravascular brachytherapy [288].




Figure 18. The intravenous MRI contrast agent $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$. The paramagnetic $4f^7 \text{Gd}^{3+}$ ion is large (ionic radius 1.2 \AA) and can accommodate eight coordinating atoms from the chelating DTPA ligand and a water molecule. Exchange of coordinated water with bulk water is important for producing contrast in the magnetic resonance image.

The ^{177}Lu radionuclide of *lutetium* ($Z=71$), half-life 6.7 days, with its β and γ emissions can be used for both therapy and SPECT imaging [289,290]. Two radiolabelled anti-epidermal growth factor receptor (EGFR) antibodies have been assessed for their EGFR-targeting and radioimmunotherapy efficacy [289]. Both display good tumour uptake and delay tumour growth significantly. Pretargeted radioimmunotherapy combining ^{177}Lu -IMP-288 peptide and antibodies can deliver a higher radiation dose to tumours than a directly labelled antibody and is currently in clinical phase I/II trials for treatment of small cell lung cancer [291].

The radioisotope ^{225}Ac of *actinium* ($Z=89$) which decays by β^- , α and β^+ (electron capture) emissions with a half-life of 10 days, is a useful radiopharmaceutical. Its cascade decay products include ^{213}Bi , also an α (and β^-) emitter useful for targeted radiotherapy [292]. Alpha-emitters are appropriate for management of minimal disease, including haematologic cancers, infections and compartmental cancers like ovarian cancer [293]. Lintusumab-Ac225 is about to enter phase I/II clinical trials in combination with Cytarabine for older patients with untreated acute myeloid leukaemia (AML) [294] and actinium-225-labelled humanized anti-CD33 monoclonal antibody HuM195 is completing phase I trials for patients with advanced myeloid malignancies [295].

5. Group 13: the boron family

As yet there is no convincing evidence that *boron* ($Z=5$) is an essential element for man. In contrast boron is thought to be essential for the growth and development of vascular plants, diatoms, marine algae and cyanobacteria [296–298]. It may play a role in the development of healthy bones and joints, and as a dietary supplement might be effective in preventing or treating arthritis [299,300]. Boron can stabilize and extend the half-life of vitamin D and estrogen, both of which are essential to bone health [300].

Boromycin is a polyether-macrolide antibiotic isolated from the Gram-positive *Streptomyces antibioticus* bacteria. It kills Gram-positive bacteria by adversely affecting the cytoplasmic membrane resulting in loss of potassium ions from the cell [301,302]. *In vitro* studies suggest that boromycin can inhibit replication of the clinically isolated HIV-1 strain and it may exert its anti-HIV activity by blocking later stage infection and the maturity step needed for replication of HIV [303]. Boron-containing compounds are in development as therapeutics that target not only microbial or neoplastic systems but cell-signalling processes that are intrinsic to many disorders [304]. Anacor Pharmaceuticals currently has several boron-containing compounds in development. Borinic picolinate (AN0128, figure 19) is a boronic acid ester with both anti-microbial and anti-inflammatory activity for acne and mild to moderate atopic




Figure 19. Two boron-containing drugs on clinical trial [305].

dermatitis (http://www.anacor.com/pdf/AAD_P108.pdf (accessed 10 November 2014)) [306]. AN2690 (Kerydin) is an oxaborole topical antifungal approved by the FDA for treatment of onychomycosis of the toenails as a result of *Trichophyton rubrum* or *Trichophyton mentagrophytes* (<http://www.anacor.com/pdf/Kerydin%20labeling.pdf> (accessed 10 November 2014)).

Aluminium ($Z = 13$) is the most abundant metal by weight in the Earth's crust and the third most abundant element after oxygen and silicon. It has no known role in human biology but there is evidence that Al may be linked to acute and chronic diseases in humans [307–309]. However problems seem to arise only in cases of kidney failure or if the kidney is underdeveloped (babies). Then Al absorption into the blood can lead to Al deposition in the brain, to dementia and even death [309]. Aluminium is present in many commercial products, including cosmetics, and Al exposure is rising [308].

Aluminium may impair mitochondrial bioenergetics via generation of reactive oxygen species which in turn leads to oxidative stress. Oxidative stress has been implicated as a factor in certain neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease [307]. Aluminium salts are used as adjuvants in vaccines. Adjuvants are believed to promote immune responses either through recruitment of antigen professional antigen-presenting cells (APCs) to the vaccination site for optimal delivery of antigens to APCs or by activation of APCs to make cytokines and prompting T-cell response [310]. Aluminium salts act by activating the nucleotide binding domain-like receptor protein-3 (NLRP3) via one of two models of phagocytosis [311]. Aluminium salts are still in use as adjuvants (table 1). Alum (hydrated potassium aluminium sulfate), while one of the oldest and most common adjuvants used, is now being reconsidered in vaccine formulations as there are questions about its toxicity [312,313].

Gallium ($Z = 31$) compounds are used in therapy and in diagnosis [314–316]. The radionuclide ^{68}Ga (half-life 1.1 h, decays by electron capture) can be efficiently generated using a $^{68}\text{Ge}/^{68}\text{Ga}$ generator, removing the need for radiopharmacies to have a cyclotron on site [317]. Its short half-life makes ^{68}Ga -labelled radiopharmaceuticals popular for clinical use, e.g. tumour imaging [314,318]. ^{67}Ga (half-life 3.3 days, electron capture followed by γ emission) scintigraphy is used in oncology to detect malignant tumours in patients [314,319], including Hodgkin's and non-Hodgkin's lymphomas [320].

Gallium nitrate ($\text{Ga}(\text{NO}_3)_3$, Ganite) can suppress the growth of subcutaneously implanted tumours [314]. It has completed a phase I clinical trial for treatment of children with brain tumours, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma and refractory solid tumours [319] and phase II trials in patients with relapsed or refractory non-Hodgkin's lymphoma [321,322]. During studies of the antineoplastic activity of GaNO_3 , it was noted that calcium levels in blood decreased in many patients [323], prompting investigations into the management of elevated blood calcium levels associated with cancer [324]. Gallium nitrate is also currently in

Table 1. Aluminium salts still in use as adjuvants [310].

aluminium salt	vaccine
aluminium phosphate	DTaP (Daptacel), DTaP-IPV/Hib (Pentacel), pneumococcal (PCV13—Prevnar13), Td (Tenivac), Tdap (Adacel)
aluminium hydroxide	DTaP (Infanrix), DTaP-IPV (Kinrix), Hep A (Havrix), Hep B (Engerix-B), human papillomavirus (HPV) (Cervarix), Tdap (Boostrix)
aluminium potassium sulfate	DT, DTaP (Tripedia), Td (Decavac)
aluminium hydroxide, aluminium phosphate	DTaP-HepB-IPV (Pediatrix), Hib (PedvaxHIB)
potassium aluminium sulfate, amorphous aluminium hydroxy phosphate-sulfate	Hib/Hep B (Comvax), Hep B (Recombivax)
amorphous aluminium hydroxy phosphate-sulfate	Hep A (Vaqta), HPV (Gardasil)
aluminium phosphate + aluminium hydroxide	Hep A/Hep B (Twinrix)

phase I clinical trials for patients suffering from cystic fibrosis [325]. Non-redox-active Ga^{3+} can inhibit (redox-active) Fe(III)-dependent pathways, including iron pathways in bacteria [326].

Indium ($Z = 49$) has no known biological role in humans. The radionuclide ^{111}In , a γ -emitter with a half-life of 2.8 days, is used in clinical diagnostic imaging. For example, ^{111}In -CHX-A DTPA Trastuzumab (Indium-Herceptin) is about to enter clinical trials for imaging breast cancer [327] and a phase II trial is evaluating the side effects of administration of ^{111}In ibritumomab tiuxetan in combination with ^{90}Y ibritumomab tiuxetan, rituximab, fludarabine, melphalan for stem cell transplants in patients with B-cell non-Hodgkin lymphoma [328].

Thallium ($Z = 81$) is best known for its toxicity, especially as Tl^+ when it can interfere with K^+ pathways (sometimes called ‘super-potassium’). The isotope ^{205}Tl (70% abundant, nuclear spin 1/2) is sensitive for NMR detection. ^{201}Tl (half-life 73 h) which decays by electron capture is used in radiodiagnostic imaging (SPECT).

6. Group 14: the carbon family

Carbon ($Z = 6$) makes up 18.5% of the body and is the second most abundant element in humans, where its oxidation states range from +4 (CO_2 , bicarbonate) to -4 (hydrocarbons). We will not discuss the ‘organic’ chemistry of life and medicines here which is, of course, extensive, but just mention recent biological and medical interest in carbon monoxide.

The body produces about 3–6 ml of CO per day from the breakdown of haem by the enzyme haem oxygenase. Since carbon monoxide is a natural metabolite with signalling functions in the body, it is of interest as a drug [329]. In particular, metal carbonyl complexes such as $[\text{Ru}(\text{CO})_3\text{Cl}(\text{glycinate})]$ (CORM-3) hold potential as carbon monoxide releasing molecules (CORMs) for the transport and delivery of CO to target sites. Such drug use may be protective against transplant organ rejection, inflammation, and endothelial oxidative damage, and perhaps provide antibiotics to combat infection [330,331].

Silicon ($Z = 14$) is present at significant levels in humans (total *ca* 21 g), but it is unclear if this element is essential to our function or not. No specific genes coding for Si are currently known for humans. Some fibrous silicate asbestos minerals are known to be health hazards [332].

Over the last three decades, much research has gone into ascertaining the importance of Si in our bodies. Silicon may be essential for bone formation [333], for synthesis of collagen and its stabilization, and matrix mineralization [333]. The ingestion of bioavailable silicon may increase




Figure 20. Structures of the photosensitizers Pc4 and purlytin.


bone mineral density, and Si supplementation in both animals and humans has a direct positive effect on bone density and strength [334].

A silicon-containing phthalocyanine (Pc4, figure 20) is a second generation photosensitizer currently in clinical trials, and can kill tumour cells and lymphoid cells via apoptosis [335,336]. Pc4 has completed phase I clinical trials for photodynamic therapy of patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides [337–339] and is entering phase I clinical trials for photodynamic therapy in stage IA–IIA cutaneous T-cell non-Hodgkin lymphoma [340].

There is no evidence to support the essentiality of *germanium* ($Z = 32$) for man; however, germanium-containing preparations are sold as health elixirs and with claimed benefits for several illnesses including cancer and AIDS [341,342]. Cases of renal failure and even death, nephropathy, anaemia, myopathy and gastrointestinal disturbances have been reported after germanium intoxication [342,343], although the mutagenicity, carcinogenicity and teratogenicity of germanium compounds appear to be generally low. [344]. Bis-2-carboxyethylgermanium sesquioxide (Ge-132) is of current interest in relation to the treatment of cancer, burns, hepatitis and some cardiovascular diseases [345,346].

Forty years ago, *tin* ($Z = 50$) was thought to be essential for the growth of animals and predicted to be essential for humans, but now there is little evidence that this is the case. We are widely exposed to tin through dinnerware and the cans used food packaging, and there are trace amounts of tin in the body (*ca* 16 mg). The only current use of Sn in clinical medicine is in the photodynamic therapy agent purlytin (Rostaporfin, Sn^{IV} ethyl etiopurpurin). Purlytin (figure 20) underwent clinical trials for different cancers, cutaneous basal cell cancer, kapososis sarcomas in AIDS patients and for breast metastases in the chest wall [347]. Many organotin compounds have anti-cancer and antiviral activity, but none has reached clinical trials [348–352]. Recent examples include tri-ⁿbutyltin(IV)lupinylsulfide hydrogen fumarate which is active against leukaemia and melanoma *in vitro* and *in vivo*.

In general, *lead* ($Z = 82$) is very toxic to humans. If inhaled or ingested, it can affect the nervous system, and long-term exposure can result in a plethora of adverse effects including anaemia, nephropathy, colic-like abdominal pains and brain damage [353–355]. In adults, almost 99% of absorbed lead accumulates in erythrocytes for between 30 and 35 days allowing it to be dispersed



Scheme 1. Production of NO by NOS enzymes [362].

to soft tissues such as the liver, aorta, brain, lung and spleen [356]. Organo-lead compounds such as alkyl-Pb^{IV} compounds are metabolized to neurotoxic metabolites. Formation of these metabolites is catalysed in the liver by cytochrome p450-dependent monooxygenases [356]. Lead inhibits the steps in haem synthesis catalysed by ALA dehydratase and ferrochelatase.

The radioisotope ²¹²Pb (half-life 10.6 h, β⁻ emission, rapidly generating the α-emitter ²¹²Bi) is of interest for targeted α-particle therapy and radioimmunotherapy [357–359]. The decay leads to the emission of two short-lived α-particles that have strong therapeutic activity on cellular nuclei [357]. The radiolabelled compound ²¹²Pb-TCMC-trastuzumab shows promising pre-clinical anti-tumour activity, binding to the extracellular domain of human epidermal growth factor receptor 2 (HER2). HER2 is a tyrosine kinase receptor that is overexpressed on the cell surface of many different cancer cell types, and upon internalization ²¹²Pb then delivers a dose of α-radiation [360].

7. Group 15: the nitrogen family (pnictogens)

The human body is *ca* 3% (total *ca* 2 kg) *nitrogen* ($Z = 7$), present in many biomolecules including amino acids, proteins, nucleobases, RNA and DNA, making it an essential element. A wide range of oxidation states are important in N biochemistry ranging from -3 (NH₃) to $+5$ (nitrate).

The inorganic chemistry of nitric oxide (NO) has attracted recent attention. This reactive free radical is an important signalling molecule in the body, responsible for regulation of numerous biological processes including neurotransmission, smooth muscle contraction and immune reactions [361]. It is produced via conversion of L-arginine to L-citrulline by nitric oxide synthases (NOS) using NADPH and oxygen (scheme 1) [362]. Three NOS isoforms have been identified, endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) [363]. Neuronal NOS is responsible for producing NO in nervous tissue and is involved in cell communication, eNOS generates NO in blood vessels and participates in vasodilation, and iNOS is located in the cardiovascular and immune systems and upon stimulation by proinflammatory cytokines produces large quantities of NO [363].

¹³N is a positron emitting isotope used in PET imaging. It has an extremely short half-life of 10 min and is therefore generated onsite in cyclotrons. ¹³N-ammonia has been in use since the 1970s for cardiac PET imaging [364]. It is administered by injection and exists as an equilibrium mixture of ¹³NH₃ (minor) and ¹³NH₄⁺ (major) in the bloodstream [365]. The neutral ¹³NH₃ molecule can easily diffuse across plasma and cell membranes and once inside myocytes re-equilibrates with its protonated form which is then trapped in glutamine via the enzyme glutamine synthase [365]. Toxic ammonia is converted into urea which is excreted by the kidneys, via the urea cycle involving six enzymes and two mitochondrial transporters.

There is *ca* 0.9 kg of the essential element *phosphorus* ($Z = 15$) in the body, up to 90% of which is in apatite in bones and teeth and the rest in extracellular fluids and soft tissue [366].

Phosphorus(III) has a well-established chemistry but is too strong a reductant to be found in most living organisms. Phosphorus(V) plays a major role in biological molecules, particularly in phosphate diester linkages in the structural framework of DNA and RNA. Polyphosphate esters are used by living cells for transport of cellular energy, especially ATP. Disruption of phosphorus homeostasis in the body can have detrimental consequences. Hypophosphatemia, low levels of phosphate in serum, has been suggested to lead to rhabdomyolysis, respiratory failure, haemolysis and cardiac failure [367]. Hyperphosphatemia (increased levels of phosphate in serum) has been linked to chronic kidney disease [368].

Bone formation from cross-linked collagen, osteocalcin and osteopontin proteins together with an equal amount of calcium phosphate mineral is carefully controlled in osteoblast cells. Osteoblast cells break down bone as part of the continual dynamic remodelling and repair processes. Phosphorus-32 (half-life 14.3 days) is a β -emitting radionuclide used in therapeutic and diagnostic oncology as well as general biochemical tracing. It is used for detection of malignant tumours, as cancer cells accumulate more phosphate than normal cells [369]. Phosphocol P32 is a ^{32}P radiolabelled drug that is used to treat different cancers and as a therapeutic for cancer-related effects such as fluid build-up in the pleura or peritoneum (<http://www.mayoclinic.org/drugs-supplements/chronic-phosphate-p-32-injection-route/description/drg-20062817> (accessed 26 August 2014)).

Arsenic ($Z = 33$) is probably most widely known for its poisonous effect in humans. Symptoms of acute arsenic poisoning include diarrhoea, vomiting, blood in the urine, cramping muscles and eventually, death. Arsenic is an ultra-trace element in the body and normal blood levels in humans are 4–30 nM with a half-life of *ca* 2 h [370]. Chronic arsenic exposure is a serious problem in many parts of the world [371]. When elevated levels of As are consumed, it is enzymatically converted to monomethyl- and dimethyl-arsenic species by arsenite methyltransferase (encoded by the *As3MT* gene), primarily in liver cells [372] and rapidly excreted in the urine. Arsenate decreases ATP levels by unravelling its synthesis through a biochemical phenomenon known as arsenolysis and produces As^{III} . Arsenic(III) has a high affinity for thiols and can inhibit enzymes such as pyruvate dehydrogenase [373].

Despite its toxic reputation, arsenic compounds do have some therapeutic efficacy and were employed as far back as the eighteenth century when a potassium bicarbonate-based solution of arsenic trioxide (As_2O_3) (figure 21) known as Fowler's solution was prescribed for a variety of illnesses [374]. Salvarsan and Neosalvarsan were used in the early twentieth century as antibiotics to treat syphilis [375]. Arsenic trioxide (As_2O_3) is an approved drug for management of promyelocytic leukaemia [376,377] and is in clinical trials for treatment of several other cancers including unresectable hepatocellular carcinoma and non-small-cell lung cancer [378,379]. In water, As_2O_3 forms $\text{As}(\text{OH})_3$ which can enter cells via glycerol transport pathways (aquaglyceroporins). Melarsoprol is an organoarsenical that is used to treat trypanosome infections in Africa [380]. Darinaparsin, *S*-dimethylarsino-glutathione, is undergoing clinical trials as a cancer therapeutic [381,382]. This drug is able to induce greater intracellular arsenic accumulation and cell death *in vitro* with lower systemic toxicity compared to arsenic trioxide [383].

Antimony ($Z = 51$)-containing compounds have been used in medicine for centuries. The most significant application is the use of organoantimonials for the treatment of leishmaniasis [384,385]. Antimony(III) potassium tartrate was prescribed in the early twentieth century for muco-cutaneous leishmaniasis and visceral leishmaniasis [384]. Unfortunately, there were severe side effects and less toxic Sb^{V} compounds were introduced in the 1940s [384]. Two formulations are still in use for leishmaniasis therapy, meglumine antimoniate (Glucantime) and sodium stibogluconate (Pentostam). It is proposed that Sb^{V} is a prodrug, reduced to Sb^{III} by the parasite or host cell [386]. The target of these antimonials is believed to be trypanothione, a low molecular weight thiol abundant in the *Leishmania* parasite [387]. Along with trypanothione reductase, trypanothione affords an intracellular reducing environment to circumvent oxidative stress thus ensure parasite survival [387,388]. Experimental studies point to Sb^{V} being reduced to Sb^{III}




Figure 21. Structures of arsenic-containing drugs [370].




Figure 22. Reduced trypanothione reductase from *Leishmania infantum* bound to NADPH and Sb^{III} . Sb^{III} is coordinated to the two redox-active catalytic cysteine residues (Cys52 and Cys57), Thr335 and His461 [389]. Reprinted with permission from Baiocco P, Colotti G, Franceschini S, Ilari A. 2009 *J. Med. Chem.* **52**, 2603–2612. Copyright © 2009 American Chemical Society.

intracellularly followed by binding of Sb^{III} to trypanothione to form a complex that can then inhibit trypanothione reductase via thiolate exchange (figure 22) [388].

Prolonged exposure to antimony is a risk for people working in metal mining, smelting and refining, refuse incineration, coal-fired power plants and indoor firing ranges and may result in respiratory irritation, pneumoconiosis, antimony spots on the skin and gastrointestinal symptoms [390]. In a therapeutic setting, toxic side-effects of antimonials are cardiotoxicity and pancreatitis both of which are commonly observed in HIV and visceral leishmaniasis co-infections [390].

Bismuth ($Z = 83$) compounds have long been used as antibacterial agents and are common today as a medication to eliminate *Helicobacter pylori*, a Gram-negative bacterium that is the causative agent of gastrointestinal illnesses such as peptic ulcers [391]. Colloidal bismuth subcitrate (De-Nol) and bismuth subsalicylate (Pepto-Bismol) are used for prevention and treatment of gastric

and duodenal ulcers [392,393]. Sulbogin is a topical ointment used for wound healing, and contains bismuth subgallate as one of its main components [394]. Bismuth subgallate acts through activation of the Hageman factor (factor XII) in the clotting cascade to quicken coagulation [395]. Bi^{3+} is a highly acidic metal ion (pK_a of aqua complex *ca* 1.5) and often forms polymeric complexes with hydroxide or oxide bridges, or citrate bridges in the case of bismuth subcitrate.

Interest in bismuth compounds as anti-cancer agents is growing due to the observation that administration of bismuth prior to chemotherapy can decrease the toxic side-effects associated with cisplatin [396,397]. Bismuth-213 is an α -emitter with a half-life of 45.6 min, prepared for clinical use from a $^{225}\text{Ac}/^{213}\text{Bi}$ generator. A phase I trial of ^{213}Bi -lintuzumab demonstrated that administration of the radiopharmaceutical was safe up to 37 MBq kg^{-1} in patients with relapsed or refractory AML [398]. The phase I/II trial of sequential administration of cytarabine and ^{213}Bi -lintuzumab for α -targeted radiotherapy in patients with AML found that ^{213}Bi -lintuzumab gave rise to remissions in patients [399].

8. Group 16: the chalcogens

Oxygen ($Z = 8$), the third most abundant in the universe (after H and He) and most abundant element in the Earth's crust by weight, is vital as O_2 to support cell respiration. We breathe air that is 21% O_2 by volume. Over half our body mass is oxygen (49/80 kg). Ground state O_2 is a triplet ($^3\text{O}_2$) and relatively unreactive, even though a strong oxidant. Excited state singlet oxygen ($^1\text{O}_2$) in contrast is highly damaging and can kill cells (the basis of photodynamic therapy). The oxidation states of oxygen in the body range from 0 (O_2) to -2 (H_2O).

Oxygen homeostasis is crucial for survival of all vertebrates. Our bodies have evolved to ensure optimal oxygenation of all our cells, starting with entry through our lungs and then circulation and delivery of oxygen within the body [400]. Oxygen is a critical electron acceptor in redox reactions that lead to the production of ATP, the direct source of energy needed for cell function [401]. Oxygen is also an important substrate for manufacture or decomposition of many cellular components, including signalling mediators [401]. Hypoxia (lack of oxygen) is an important factor in development of severe pathologies including myocardial and cerebral ischaemia and cancer [400]. Hyperoxia (excess supply of O_2 in tissues and organs) can also have detrimental consequences such as production of high concentrations of reactive oxygen species (ROS: $^1\text{O}_2$, O_2^- , H_2O_2 , OH^-), disrupting the balance of oxidant and antioxidants and causing damage to cells and tissues [402].

Understanding the role of ROS species for signalling in the body is an important area of research [403]. Apart from its role as a destructive oxidant to ward off pathogens, H_2O_2 fulfils the role of 'secondary messenger': its enzymatic production and degradation as well as requirement for the oxidation of thiols give rise to the conditions appropriate for signalling [403]. The hypoxia-inducible factor (HIF) is a transcription factor that reacts to pathophysiologically low levels of oxygen via upregulation, setting off biological responses to hypoxia [404]. The HIF prolyl hydroxylase domain (PHD) enzymes selectively hydroxylate proline residues of HIF. The dependence of HIF protein levels on the concentration of O_2 present, mediated by the PHD enzymes, forms the basis for one of the most significant biological sensor systems of tissue oxygenation in response to ischemic and inflammatory events [404]. As a result, pharmacological inhibition of these enzymes, resulting in stabilization of HIF, has therapeutic potential for treating conditions of tissue stress and injury [404].

Sulfur ($Z = 16$) is an essential element, involved in numerous biochemical processes in oxidation states ranging from -2 (sulfide) to $+6$ (sulfate). It is the seventh most abundant element in the body (*ca* 160 g).

Sulfur compounds act as both electron donors and electron acceptors in metabolic reactions. Methionine (Met), the thioether amino acid, manages major metabolic and catalytic activities, initiates protein synthesis and undergoes reversible redox reactions to protect protein integrity [405]. The abundant intracellular thiol tripeptide glutathione (GSH) is a defensive biomolecule

against toxic xenobiotics such as drugs, pollutants and carcinogens [406]. As an antioxidant, GSH participates in protection of the cell from oxidative stress either directly or as a cofactor of glutathione peroxidases [406]. Thioredoxins, with a dithiol-disulfide active site, are a class of redox proteins that participate in redox signalling in the body and are coded by the *TXN* gene [407]. Cysteine (Cys) is biosynthesized in humans and participates in enzymatic reactions as a nucleophile. Keratin's disulfide bonds are mostly responsible for the strength of this protein that is present in our skin, hair and nails.

Hydrogen sulfide (H_2S), a highly toxic gas, is a mammalian messenger molecule. It is largely formed from Cys or its derivatives by the enzymes cystathionine β -synthase and cystathionine γ -lyase (CSE) [408]. One mechanism of H_2S signalling is the sulfhydration (persulfide RSSH formation) of reactive Cys residues in target proteins [408]. This sulfhydration is responsible for the regulation of inflammation and endoplasmic reticulum stress signalling as well as of vascular tension [409]. A number of additional pharmacological targets for H_2S have been identified including K(ATP), the ATP-sensitive potassium channel, and transient receptor potential channels, NF- κ B nuclear translocation, extracellular signal-regulated kinase and Akt (protein kinase B) [410]. Atherosclerosis is a chronic disease that is considered to be the leading cause of cardiovascular morbidity and mortality [411]. Endogenous H_2S production could be beneficial for prevention and treatment of atherosclerosis [412,413], since decreased levels of endogenous H_2S induced by genetic deletion of CSE quickens the disease [412]. Sulfide is ubiquitous in the iron sulfur redox proteins ferredoxins. The Fe/S clusters are assembled on a scaffold protein in mitochondria, transported out and then incorporated into ferredoxins.

There is only about 4 mg of *selenium* ($Z = 34$) in the body, but it is essential and its genetic codes are now well known. Selenium exerts its biological functions through selenoproteins.

Unlike the 20 standard amino acids, Sec is biosynthesized from serine on its tRNA. The insertion of Se donated by selenophosphate into the amino acid serine to give the 21st amino acid selenocysteine is encoded by the termination codon UGA, which is one of three termination codons for mRNA translation in non-selenoprotein genes, resulting in 25 selenoproteins with redox and signalling functions [414]. Recognition of the UGA codon as a Sec insertion site instead of stop requires a Sec insertion sequence element in selenoprotein mRNAs and a unique selenocysteyl-tRNA, both of which are recognized by specialized protein factors.

Selenium has an antioxidant effect as selenocysteine in the enzyme glutathione peroxidase (GSH-Px) and is also present in other selenoproteins such as the type 1 iodothyronine 59-deiodinase, important in the activation and deactivation of thyroid hormones [414]. However, the functions of most selenoproteins and Se-containing biomolecules still remain unclear. Selenomethionine and Se-methyl-seleno-L-cysteine are in phase I trials for chemopreventive treatment of prostate cancer in healthy individuals [415]. Selenium sulfide is an antifungal agent that is used as an additive to shampoos to treat dandruff and certain types of dermatitis [416].

Tellurium ($Z = 52$) has been regarded as a toxic, non-essential element but studies of the pharmacological properties of both organic and inorganic tellurium compounds have revealed some potential applications in medicine [417]. One such drug is AS101, a non-toxic Te^{IV} compound that is in phase II clinical trials for treatment of external genital warts, as an additive to the standard chemotherapy regimen of newly diagnosed elderly AML patients and AML transformed myelodysplastic syndrome patients and as a preventative agent of bone marrow toxicity due to chemotherapy in cancer patients [418–420]. A study of the oral and intraperitoneal administration of AS101 revealed that the drug significantly reduced clinical manifestations of inflammatory bowel diseases [421]. In a dextran sodium sulfate-induced colitis model, AS101 exerted its anti-inflammatory and anti-apoptotic activities through the downregulation of colonic cytokine levels (IL-17 and IL-1 β) and by the blockade of leucocyte (neutrophil and macrophage) migration into the colon [421].




Figure 23. Ionic radii of the halide ions and enthalpy of hydration [27,28].

9. Group 17: the halogens

There is a lot of *fluorine* ($Z=9$) in the body (total *ca* 3 g) and in the form of fluoride may be essential, but surprisingly little appears to be known about specific uptake and transport mechanisms. There may be specific HF transport proteins (in acidic conditions, *vide infra*) and F⁻/H⁺ cotransporter or F⁻/OH⁻ antiporter proteins [422].

Fluoride is the smallest and most strongly basic of the halide ions, figure 23. Fluoride is added to drinking water and its presence has a beneficial effect on teeth and bones [423]. Fluoride has a high affinity for ‘hard’ metal ions such as Ca²⁺. It displaces hydroxyl ions in hydroxyapatite (Ca₅(PO₄)₃OH), which is the main constituent of teeth and bones, to a stronger and harder fluoroapatite (Ca₅(PO₄)₃F) [423]. It is recommended that small levels of 26–35 μM of fluoride can strengthen enamel. Gross systemic exposure to fluorides could alter bone homeostasis and dental enamel development [424]. Dental fluorosis is dependent on fluoride dose as well as timing and duration of exposure. In many parts of the world the amount of fluoride in ground water exceeds the recommended levels giving rise to fluorosis which then progresses to skeletal fluorosis.

Fluorides seem to regulate their activity through the mitogen-activated protein kinases MAPK signalling pathway which can result in alterations to gene expression, cell stress and cell death [424]. Fluoride metabolism in our bodies is pH dependent as the coefficient of permeability of lipid bilayer membranes to hydrogen fluoride is a million times that of the fluoride ion [425]. This translates to fluoride being able to readily cross cell membranes as HF in reaction to a pH gradient between body fluid compartments which is why following ingestion, levels of fluoride in blood plasma rapidly rise because of fast absorption in the stomach [425]. Aluminium fluoride and beryllium fluoride are used as inhibitors of many enzymes. They act as mimics of phosphate and can activate the heterotrimeric GTP-binding proteins [426]. There are more numerous fluorinated pharmaceuticals available as anaesthetics, antibiotics, anti-tumour and anti-inflammatories [427,428]. Fluorine-18 labelled deoxyglucose (electron capture, half-life 110 min) is one of the most widely used tracers for PET imaging to detect changes in glucose metabolism in pathophysiological processes [429]. ¹⁸F-fluorodeoxyglucose-positron emission tomography (¹⁸F-FDG-PET) is also used for screening, localization and follow-up of hypermetabolic processes including malignancies, infections and autoimmune processes [430].

Chlorine ($Z=17$) is prevalent in the body (*ca* 96 g). The concentration of Cl⁻ is high in body fluids (*ca* 100 mM in blood) and is regulated in cellular compartments (e.g. 25 mM in the cytoplasm and 4 mM in the nucleus of cells). Unlike fluorine, but in common with bromine and iodine, chlorine can exist in oxidized forms in the body.




Figure 24. The three and four iodine atoms in triiodothyronine and thyroxine, respectively. T₃ is the more active form of the hormone produced from T₄ by the action of a Se-dependent deiodinase (peroxidase) enzyme.

Membrane transport proteins for Cl⁻ have been characterized. Epithelial transport of Cl⁻ (and SCN⁻) in many organs including the intestines, lungs, sweat glands and kidneys is mediated by the cystic fibrosis transmembrane conductance regulator (CFTR) [431], a 1480 amino acid cAMP-activated ATP-gated anion-channel glycoprotein. Mutations in the gene encoding CFTR can lead to reduction in either its transport capacity for chloride or cell surface expression causing the condition cystic fibrosis [432,433] and a type of male sterility as a result of congenital absence of the vas deferens [434].

Higher oxidation states of chlorine also play a role in the body. Hypochlorous acid (HOCl) is a strong oxidant (bleach!) produced by white blood cells (neutrophils) and can eradicate all types of bacteria. Even though it is employed by our immune system, it can also be lethal to our own cells depending on the dose [435]. In neutrophils, the haem enzyme myeloperoxidase uses hydrogen peroxide to convert chloride to HOCl [436].

There are significant amounts of *bromine* ($Z = 35$) in the body (*ca* 0.2 g) and in blood (3.2–5.6 $\mu\text{g ml}^{-1}$), arising from a daily dietary intake of bromide *ca* 2–8 mg (fish, grains and nuts), and there is growing evidence that it is essential. Eosinophil peroxidase is a haloperoxidase enzyme encoded for by the *EPX* gene and produces both HOBr and HOCl [437]. Even though it can produce HOCl, it preferentially chooses bromide over chloride to produce brominating agents even at physiological concentrations, when chloride is vastly more abundant [438].

A recent paper has concluded that bromine is an essential trace element for all animals [439], since Br⁻ (on conversion to HOBr) is a required cofactor for peroxidase-catalysed formation of sulfilimine cross-links in a posttranslational modification essential for tissue development within the collagen IV scaffold of basement membranes [439]. More research is needed to confirm the nutritional benefits of bromine.

Although there is only about 16 mg in the body, *iodine* ($Z = 53$) is essential for the thyroid gland in the form of thyroid hormones, especially triiodothyronine (T₃) (figure 24) and thyroxine (tetraiodothyronine, T₄), synthesized from iodine (iodide) and tyrosine from the protein thyroglobulin by the enzyme thyroid peroxidase. These hormones play a major role in regulating growth and development. Iodine deficiency results in goitre (Derbyshire neck), avoided by supplementation of, e.g. table salt with iodate. The importance of C–I bonds can be contrasted with the behaviour of the lighter halogens in the body.

The Na⁺/I⁻ symporter (NIS) plays an important role in iodine metabolism and thyroid regulation [440]. NIS is an integral plasma membrane glycoprotein and thyroidal I⁻ transport from the bloodstream is made possible by selective targeting of NIS to the basolateral membrane [440]. It also regulates transport of I⁻ in other tissues, including salivary glands, gastric mucosa and lactating mammary gland, where I⁻ is translocated into the milk for thyroid hormone biosynthesis by the nursing newborn [441]. NIS is an ideal foundation for diagnostic and therapeutic management of thyroid cancer and its metastases using radioiodide [442].

Transduction of NIS into various kinds of cancer cells to render them susceptible to destruction with radioiodide has been reported [440,443]. Remarkably, more than 80% of human breast cancer samples express endogenous NIS, making the potential use of radioiodide for diagnosis and treatment possible [444].

Astatine-211 is an α -emitter with a half-life of 7.2 h. α -Emitters have unique features that make them ideal for elimination of focal pockets of tumour cells that are predominantly located in normal neural tissue in the CNS [445]. For example, they can be used for targeted therapy without risk of adjacent normal tissue toxicity that sometimes occurs with β -emitters; this feature is ideal for sensitive areas such the CNS [445]. A pilot clinical study has evaluated the feasibility, safety and efficacy of the chimeric antitenascin mAb 81 C6 labelled with ^{211}At in patients with recurrent malignant brain tumours [445]. The radiotherapeutic agent ^{211}At -MX35 F(ab')₂ has also completed phase I pharmacokinetic studies in women in complete clinical remission of recurrent ovarian cancer [446].

10. Group 18: the noble gases

Exploration of the noble gases in medicine has been limited, although *helium* ($Z=2$) is being considered for adjunct therapy for respiratory ailments such as asthma, croup and bronchiolitis [447]. It has also shown efficacy in protection of the myocardium from ischaemia, though the mechanism of protection is unclear [411]. Employment of He in the operating theatre as a replacement for CO₂ to insufflate the abdomens of patients undergoing laparoscopic abdominal procedures is being evaluated [448]. Helium is a better alternative as it prevents respiratory acidosis in patients with co-morbid conditions that cause CO₂ retention [448]. Helium ion microscopy offers imaging of organs in very fine detail and hyperpolarized helium (HP ^3He) for pulmonary MRI can be used for imaging of both normal and diseased lungs [447,449].

About 1% of the air we breathe is *argon* ($Z=18$), mostly arising from the radioactive decay of ^{40}K in the Earth's crust. Argon has found application in electrosurgery; gas discharges can induce mainly superficial thermal effects on tissue in a non-contact manner (argon plasma coagulation) [450]. It was first used in open surgery in the 1970s and then later adapted for endoscopy [451,452]. Examples of its use include repair of haemorrhages that can occur during surgery or ulcers, injured blood vessels, varices and tumours, as well as devitalization and shrinkage of tumours and obstructing tissues [450].

Krypton ($Z=36$) gas, as the quadrupolar isotope ^{83}Kr (nuclear spin $I=9/2$, natural abundance 11.5%) can be used for imaging (MRI) of airways particularly to differentiate between hydrophobic and hydrophilic surfaces [453,454].

Xenon ($Z=54$) is used as a general anaesthetic. It has a high affinity for the glycine site on the *N*-methyl-D-aspartate (NMDA) receptor, and unlike most other clinical NMDA receptor antagonists, it is not neurotoxic [455,456]. Of particular note is the use of xenon as an additive in the ventilation mix for a newborn baby to prevent brain injury (<http://www.wales.nhs.uk/sitesplus/863/news/16104> (accessed 29 August 2014)). Xenon-133 (half-life 5.2 days, β^- decay) is used in radioimaging of the lungs by SPECT [457], and measurement of blood flow [458]. Hyperpolarized ^{129}Xe (nuclear spin $I=1/2$, 26% abundant) is an MRI contrast agent used for imaging of the flow of gas in the lungs [459].

Radon ($Z=86$) is a toxic radioactive (dense) gas produced from the breakdown of long-lived (billions of years) radioactive uranium (and thorium) via ^{226}Ra in soils, rocks and water. Decay of radon yields radioactive solids (radon daughters) which are α -emitters and attach to dust particles and are then inhaled. This inhalation has been linked to lung cancer [460,461]. Radon exposure may also lead to production of toxic reactive oxygen species. Dissolved radon in a pregnant woman's bloodstream can have detrimental consequences including retardation of brain development and even death [460]. Accumulation of radon in homes is a potential problem.

Table 2. Examples of human genetic (proteomic) codes for the elements of the periodic table.

atomic number	element	examples of genetic codes
1	H	uptake and transport of H-containing molecules (C–H, N–H, etc.), proteins, bicarbonate (CO ₂) for pH control
6	C	general: C–H, C=O, etc. taken up in building blocks (amino acids, fatty acids, etc.) regulation of CO ₂ , carbonate, CO
7	N	general: N–H, N–C, etc., amino acids, nucleotides NOSs; conversion of NH ₃ into urea (enzymes and transporters)
8	O	for example, O ₂ uptake, transport (haemoglobin) and storage (myoglobin), conversion of O ₂ to H ₂ O ₂ , and H ₂ O by mitochondrial proteins, various enzymes (e.g. superoxide dismutase, catalase) O ₂ -sensor proteins (e.g. HIF)
9	F	F [−] /H ⁺ cotransporter or a F [−] /OH [−] antiporter ?? Biochemistry poorly understood
11	Na	membrane pumps Na ⁺ /K ⁺ ATPase
12	Mg	MAGT1, magnesium transporter 1
15	P	kinases, phosphatases, nucleotides
16	S	thiol/disulfide and Met in proteins; sulfide in ferredoxins
17	Cl	chloride channel: CFTR
19	K	membrane pumps Na ⁺ /K ⁺ ATPase
20	Ca	Ca ²⁺ -sensor protein troponin; Ca ²⁺ -ATPase membrane pump; calmodulin transduces Ca ²⁺ signals in cells
25	Mn	most abundant Mn protein glutamine synthetase; Mn superoxide dismutase in mitochondria
26	Fe	non-haem Fe proteins <i>ca</i> 1% of human proteome
27	Co	uptake and carrier proteins for vitamin B12
29	Cu	Cu proteins <i>ca</i> 1% of human proteome
30	Zn	Zn ²⁺ proteins <i>ca</i> 10% of human proteome
34	Se	25 selenoproteins with redox and signalling functions
42	Mo	four Mo enzymes (xanthine oxidoreductase and sulfite oxidase families); taken up only as molybdate?
53	I	thyroid hormones thyroxine (T4) and triiodothyronine (T3) synthesised from tyrosine residues in protein thyroglobulin
potentially essential elements		
14	Si	role in bone mineralization?
23	V	role in phosphate biochemistry?
24	Cr	influence on glucose metabolism?
28	Ni	essential for some microorganisms allergenic: MHCII-Ni-peptide recognition by T cells
35	Br	essential (as HOBr?) for killing invading microorganisms? essential for assembly of collagen IV scaffolds in tissue development—therefore essential for all animals?
50	Sn	once thought to be essential for animal growth

Prevalent isotopes are ^{222}Rn (from ^{238}U), an α -emitter with a half-life of 3.8 days, and ^{220}Rn (α -emitter, half-life 56 s) from the α -decay of ^{224}Ra .

11. Conclusion

We have reviewed very briefly the role of the elements of the periodic table in human life. In particular we have tried to identify which elements are essential for man and to indicate other elements which are or can be used in diagnosis and therapy. There is much medicinal inorganic chemistry still to be explored. The field is in its infancy compared to medicinal organic chemistry. More detailed background to the biological chemistry of the elements, including the influence of the environment on the natural selection of the elements by animals can be found in the recent publications by Williams *et al.* [462–464]. It is not easy to compile a definitive list of essential elements. Elements which are added to mineral supplements these days are largely there as a result of nutritional experiments carried out many years ago [5–20]. Such experimental studies on animal growth under defined nutritional conditions are expensive and the interdependence of the biochemistry of the elements and various organic cofactors can complicate the interpretation. Moreover, not only do we wish to know which elements are essential for normal growth, but also what their biochemical functions are and which particular species (chemical forms of the element) are essential.

There are many interesting examples of where a biological function requires the synergistic action of two or more elements. For example, a Se enzyme deiodinates the thyroid hormone T_4 [465], copper ceruloplasmin oxidizes iron and assists with its transport [466], cytochrome oxidase has both copper and iron in its active site for conversion of oxygen into water, cytoplasmic superoxide dismutase uses both copper and zinc to convert superoxide into oxygen and water, and the close cooperation between iron (Fe^{II} and Fe^{III}) and sulfur (sulfide and cysteine thiolate) is evident in ubiquitous ferredoxin proteins which are critical for electron storage and transport.

Since the sequence of the human genome (and many others) is now known, it is timely to ask the question ‘can we recognize genetic codes for essential elements?’ Our conclusions are listed in table 2, a list which produces 20 essential elements and six other potentially essential elements.

This short journey through the periodic table illustrates that, as yet, we are unable to understand the role of many elements found in the body in terms of genetic codes. Much modern drug design now relies on target-based design—drugs which target specific gene products (proteins/enzymes). The inventive use of minerals in medicines is therefore in danger of being abandoned. It is worth recalling the ancient Chinese approach—the use of *stone drugs* (*mineral drugs*) developed over a period of some 2000 years, preparations from natural sources (minerals and animal fossils) that in some cases contain up to 35 elements [467]. Synergistic effects may well arise from combinations of elements (and organic compounds such as vitamins). Many exciting challenges remain in this field.

Acknowledgements. We thank members of COST Action CM1105 and colleagues at the University of Hong Kong (where P.J.S. is a visiting professor) for stimulating discussions.

Funding statement. We thank the National Research Foundation (NRF) of South Africa (Fellowship for P.C.) and ERC (grant no. 247450), EPSRC (grant no. EP/F034210/1) and BBSRC for support.

References

1. Fraga CS. 2005 Relevance, essentiality and toxicity of trace elements in human health. *Mol. Aspects Med.* **26**, 235–244. (doi:10.1016/j.mam.2005.07.013)
2. Sekirov I, Russell SL, Antunes LCM, Finlay BB. 2010 Gut microbiota in health and disease. *Physiol. Rev.* **90**, 859–904. (doi:10.1152/physrev.00045.2009)
3. Savage DC. 1977 Microbial ecology of the gastrointestinal tract. *Annu. Rev. Microbiol.* **31**, 107–133. (doi:10.1146/annurev.mi.31.100177.000543)

4. Berg RD. 1996 The indigenous gastrointestinal microflora. *Trends Microbiol.* **4**, 430–435. (doi:10.1016/0966-842X(96)10057-3)
5. Nielsen FH. 1999 Ultratrace minerals. In *Modern nutrition in health and disease*, 9th edn (eds ME Shils, JA Olsen, M Shike, AC Ross), pp. 283–303. Baltimore, MD: Williams and Wilkins.
6. Sigel A, Sigel H, Sigel RKO. 2013 *Interrelations between essential metal ions and human diseases*. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
7. Schwarz K. 1976 Essentiality and metabolic functions of selenium. *Med. Clin. N. Am.* **60**, 745–758.
8. Schwarz K, Pathak KD. 1975 The biological essentiality of selenium, and the development of biologically active organoselenium compounds of minimum toxicity. *Chem. Scripta* **8A**, 85–95.
9. Schwarz K, Foltz CM. 1957 Selenium as an integral part of Factor 3 against dietary necrotic liver degeneration. *J. Am. Chem. Soc.* **79**, 3292–3293. (doi:10.1021/ja01569a087)
10. Schwarz K, Stesney J, Foltz CM. 1959 Relation between selenium traces in L-cystine and protection against dietary liver necrosis. *Metabolism* **8**, 88–90.
11. Schwarz K, Milne DB, Vinuyard E. 1970 Growth effects of tin compounds in rats in a trace element-controlled environment. *Biochem. Biophys. Res. Commun.* **40**, 22–29. (doi:10.1016/0006-291X(70)91040-5)
12. Schwarz K, Milne DB. 1972 Growth-promoting effects of silicon in rats. *Nature* **239**, 333–334. (doi:10.1038/239333a0)
13. Schwarz K, Spallholz J. 1976 Growth effects of small cadmium supplements in rats maintained under trace-element controlled conditions. *Fed. Proc.* **35**, 225.
14. Nielsen FH. 1996 How should dietary guidance be given for mineral elements with beneficial actions or suspected of being essential? *J. Nutr.* **126**, 2377S–2385S.
15. Nielsen FH. 2000 Evolutionary events culminating in specific minerals becoming essential for life. *Eur. J. Nutr.* **39**, 62–66. (doi:10.1007/s003940050003)
16. Nielsen FH. 2000 Importance of making dietary recommendations for elements designated as nutritionally beneficial, pharmacologically beneficial, or conditionally essential. *J. Trace Elem. Exp. Med.* **13**, 113–129. (doi:10.1002/(SICI)1520-670X(2000)13:1<113::AID-JTRA13>3.0.CO;2-D)
17. Nielsen FH. 1984 Fluoride, vanadium, nickel, arsenic, and silicon in total parenteral nutrition. *Bull. N.Y. Acad. Med.* **60**, 177–195.
18. Frieden E. 1985 New perspectives on the essential trace elements. *J. Chem. Educ.* **62**, 917–923. (doi:10.1021/ed062p917)
19. Berner YN, Shuler TR, Nielsen FH, Flombaum C, Farkouh SA, Shiku M. 1989 Selected ultratrace elements in total parenteral nutrition solutions. *Am. J. Clin. Nutr.* **50**, 1079–1083.
20. Nielsen FH. 1998 Ultratrace elements in nutrition: current knowledge and speculation. *J. Trace Elem. Exp. Med.* **11**, 251–274. (doi:10.1002/(SICI)1520-670X(1998)11:2/3<251::AID-JTRA15>3.0.CO;2-Q)
21. Wike-Hooley JL, Haveman J, Reinhold HS. 1984 The relevance of tumour pH to the treatment of malignant disease. *Radiother. Oncol.* **2**, 343–366. (doi:10.1016/S0167-8140(84)80077-8)
22. Mindell JA. 2012 Lysosomal acidification mechanisms. *Annu. Rev. Physiol.* **74**, 69–86. (doi:10.1146/annurev-physiol-012110-142317)
23. Mayle KM, Le AM, Kamei DT. 2012 The intracellular trafficking pathway of transferrin. *Biochim. Biophys. Acta* **1820**, 264–281. (doi:10.1016/j.bbagen.2011.09.009)
24. Matthews A, Zhu X-K, O'Nions K. 2001 Kinetic iron stable isotope fractionation between iron (-II) and (-III) complexes in solution. *Earth Planet. Sci. Lett.* **192**, 81–92. (doi:10.1016/S0012-821X(01)00432-0)
25. Zhu XK *et al.* 2002 Mass fractionation processes of transition metal isotopes. *Earth Planet. Sci. Lett.* **200**, 47–62. (doi:10.1016/S0012-821X(02)00615-5)
26. Gant TG. 2014 Using deuterium in drug discovery: leaving the label in the drug. *J. Med. Chem.* **57**, 3595–3611. (doi:10.1021/jm4007998)
27. Shannon R. 1976 Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. *Acta Crystallogr. A* **32**, 751–767. (doi:10.1107/S0567739476001551)
28. Smith DW. 1977 Ionic hydration enthalpies. *J. Chem. Educ.* **54**, 540–541. (doi:10.1021/ed054p540)

29. Dawson EB. 1991 The relationship of tap water and physiological levels of lithium to mental hospital admission and homicide in Texas. In *Lithium in biology and medicine* (eds GN Schrauzer, KF Klippel), pp. 171–187. Weinheim, Germany: VCH.
30. Dawson EB, Moore TD, McGanity WJ. 1972 Relationship of lithium metabolism to mental hospital admission and homicide. *Dis. Nerv. Syst.* **33**, 546–556.
31. Dawson EB, Moore TD, McGanity WJ. 1970 The mathematical relationship of drinking water lithium and rainfall on mental hospital admission. *Dis. Nerv. Syst.* **31**, 1–10.
32. Birch NJ. 1995 Lithium in medicine. In *Handbook of metal-ligand interactions in biological fluids* (ed. G Berthon), pp. 1274–1281. New York, NY: Marcel Dekker.
33. Gould TD, Manji HK. 2005 Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. *Neuropsychopharmacology* **30**, 1223–1237. (doi:10.1038/sj.npp.1300731)
34. Lowthert L *et al.* 2012 Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. *Biol. Mood Anxiety Disord.* **2**, 15. (doi:10.1186/2045-5380-2-15)
35. Chen CH *et al.* 2014 Variant GADL1 and response to lithium therapy in bipolar I disorder. *N. Engl. J. Med.* **370**, 119–128. (doi:10.1056/NEJMoa1212444)
36. Pohl HR, Wheeler JS, Murray HE. 2013 Sodium and potassium in health and disease. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 29–47. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
37. Helm L, Merbach AE. 1999 Water exchange on metal ions: experiments and simulations. *Coord. Chem. Rev.* **187**, 151–181. (doi:10.1016/S0010-8545(99)90232-1)
38. Samat SB, Green S, Beddoe AH. 1997 The ⁴⁰K activity of one gram of potassium. *Phys. Med. Biol.* **42**, 407–413. (doi:10.1088/0031-9155/42/2/012)
39. Relman AS. 1956 The physiological behavior of rubidium and cesium in relation to that of potassium. *Yale J. Biol. Med.* **29**, 248–262.
40. Tout D, Tonge CM, Muthu S, Arumugam P. 2012 Assessment of a protocol for routine simultaneous myocardial blood flow measurement and standard myocardial perfusion imaging with rubidium-82 on a high count rate positron emission tomography system. *Nucl. Med. Commun.* **33**, 1202–1211. (doi:10.1097/MNM.0b013e3283567554)
41. Beller GA, Bergmann SR. 2004 Myocardial perfusion imaging agents: SPECT and PET. *J. Nucl. Cardiol.* **11**, 71–86. (doi:10.1016/j.nuclcard.2003.12.002)
42. Pais I, Jones Jr JB. 1997 *The handbook of trace elements*. Boca Raton, FL: CRC Press.
43. Wilkinson SM *et al.* 2014 The first CNS-active carborane: a novel P2X₇ receptor antagonist with antidepressant activity. *ACS Chem. Neurosci.* **5**, 335–339. (doi:10.1021/cn500054n)
44. Wang Y, Dai S. 2013 Structural basis of metal hypersensitivity. *Immunol. Res.* **5**, 83–90. (doi:10.1007/s12026-012-8351-1)
45. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU. 2005 T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. *Toxicology* **209**, 101–107. (doi:10.1016/j.tox.2004.12.015)
46. Fontenot AP, Maier LA. 2005 Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. *Trends Immunol.* **26**, 543–549. (doi:10.1016/j.it.2005.08.004)
47. Dai S, Falta MT, Bowerman NA, McKee AS, Fontenot AP. 2013 T cell recognition of beryllium. *Curr. Opin. Immunol.* **25**, 775–780. (doi:10.1016/j.coi.2013.07.012)
48. Dai S, Murphy GA, Crawford F, Mack DG, Falta MT, Marrack P, Kappler JW, Fontenot AP. 2010 Crystal structure of HLA-DP2 and implications for chronic beryllium disease. *Proc. Natl Acad. Sci. USA* **107**, 7425–7430. (doi:10.1073/pnas.1001772107)
49. Falta MT *et al.* 2013 Identification of beryllium-dependent peptides recognized by CD4⁺ T cells in chronic beryllium disease. *J. Exp. Med.* **210**, 1403–1418. (doi:10.1084/jem.20122426)
50. Hartwig A. 2001 Role of magnesium in genomic stability. *Mutat. Res.* **475**, 113–121. (doi:10.1016/S0027-5107(01)00074-4)
51. Yang W, Lee JY, Nowotny M. 2006 Making and breaking nucleic acids: two-Mg²⁺-ion catalysis and substrate specificity. *Mol. Cell* **22**, 5–13. (doi:10.1016/j.molcel.2006.03.013)
52. Selmer M, Dunham CM, Murphy 4th FV, Weixlbaumer A, Petry S, Kelley AC, Weir JR, Ramakrishnan V. 2006 Structure of the 70S ribosome complexed with mRNA and tRNA. *Science* **313**, 1935–1942. (doi:10.1126/science.1131127)
53. Klein DJ, Moore PB, Steitz TA. 2004 The contribution of metal ions to the structural stability of the large ribosomal subunit. *RNA* **10**, 1366–1379. (doi:10.1261/rna.7390804)
54. Beaven GH, Parmar J, Nash GB, Bennett BM, Gratzler WB. 1990 Effect of magnesium ions on red cell membrane properties. *J. Membr. Biol.* **118**, 251–257. (doi:10.1007/BF01868609)

55. Payandeh J, Pfoh R, Pai EF. 2013 The structure and regulation of magnesium selective ion channels. *Biochim. Biophys. Acta* **1828**, 2778–2792. (doi:10.1016/j.bbamem.2013.08.002)
56. Cohen JI. 2000 Epstein-Barr virus infection. *N. Engl. J. Med.* **343**, 481–492. (doi:10.1056/NEJM200008173430707)
57. Chaigne-Delalande B *et al.* 2013 Mg²⁺ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. *Science* **341**, 186–191. (doi:10.1126/science.1240094)
58. Toyoshima C, Nakasako M, Nomura H, Ogawa H. 2000 Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. *Nature* **405**, 647–655. (doi:10.1038/35015017)
59. Brini M, Cali T, Ottolini D, Carafoli E. 2013 The plasma membrane calcium pump in health and disease. *FEBS J.* **280**, 5385–5397. (doi:10.1111/febs.12193)
60. Silver IA, Murrills RJ, Etherington DJ. 1988 Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. *Exp. Cell Res.* **175**, 266–276. (doi:10.1016/0014-4827(88)90191-7)
61. Delaissé JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. 2003 Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. *Microsc. Res. Tech.* **61**, 504–516. (doi:10.1002/jemt.10374)
62. Moonga BS, Davidson R, Sun L, Adebajo OA, Moser J, Abedin M, Zaidi N, Huang CL, Zaidi M. 2001 Identification and characterization of a sodium/calcium exchanger, NCX-1, in osteoclasts and its role in bone resorption. *Biochem. Biophys. Res. Commun.* **283**, 770–775. (doi:10.1006/bbrc.2001.4870)
63. Li JP, Kajiya H, Okamoto F, Nakao A, Iwamoto T, Okabe K. 2007 Three Na⁺/Ca²⁺ exchanger (NCX) variants are expressed in mouse osteoclasts and mediate calcium transport during bone resorption. *Endocrinology* **148**, 2116–2125. (doi:10.1210/en.2006-1321)
64. Surdacka A, Stopa J, Torlinski L. 2007 *In situ* effect of strontium toothpaste on artificially decalcified human enamel. *Biol. Trace Elem. Res.* **116**, 147–153. (doi:10.1007/BF02685927)
65. Nielsen SP. 2004 The biological role of strontium. *Bone* **35**, 583–588. (doi:10.1016/j.bone.2004.04.026)
66. Querido W, Campos AP, Martins Ferreira EH, San Gil RA, Rossi AM, Farina M. 2014 Strontium ranelate changes the composition and crystal structure of the biological bone-like apatite produced in osteoblast cell cultures. *Cell Tissue Res.* **357**, 793–801. (doi:10.1007/s00441-014-1901-1)
67. Stahl K, Frankaer CG, Raffalt AC, Sørensen SR, Andersen JET. 2011 Polymeric strontium ranelate nonahydrate. *Acta Crystallogr. Sect. E Struct. Rep. Online* **67**, m471–m472. (doi:10.1107/S1600536811010099)
68. Meunier PJ *et al.* 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *N. Engl. J. Med.* **350**, 459–468. (doi:10.1056/NEJMoa022436)
69. Reginster J, Deroisy R, Jupsin I. 2003 Strontium ranelate: a new paradigm in the treatment of osteoporosis. *Drugs Today* **39**, 89–101. (doi:10.1358/dot.2003.39.2.799416)
70. Hahn GS. 1999 Strontium is a potent and selective inhibitor of sensory irritation. *Dermatol. Surg.* **25**, 689–694. (doi:10.1046/j.1524-4725.1999.99099.x)
71. Tomblyn M. 2012 The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. *Cancer Control* **19**, 137–144.
72. Blake GM, Zivanovic MA, Blaquièrè RM, Fine DR, McEwan AJ, Ackery DM. 1988 Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. *J. Nucl. Med.* **29**, 549–557.
73. Fuster D, Herranz D, Vidal-Sicart S, Muñoz M, Conill C, Mateos JJ, Martín F, Pons F. 2000 Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. *Nucl. Med. Commun.* **21**, 623–626. (doi:10.1097/00006231-200007000-00004)
74. Kraeber-Bodéré F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. 2000 Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. *Eur. J. Nucl. Med.* **27**, 1487–1493. (doi:10.1007/s002590000315)
75. Gunawardana DH, Lichtenstein M, Better N, Rosenthal M. 2004 Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. *Clin. Nucl. Med.* **29**, 81–85. (doi:10.1097/01.rlu.0000109721.58471.44)
76. Bruland OS, Nilsson S, Fisher DR, Larsen RH. 2006 High-linear energy transfer irradiation targeted to skeletal metastases by the α -emitter ²²³Ra: adjuvant or alternative

- to conventional modalities? *Clin. Cancer Res.* **12**, 6250s–6257s. (doi:10.1158/1078-0432.CCR-06-0841)
77. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. 2002 Significant antitumor effect from bone-seeking, α -particle-emitting ^{223}Ra demonstrated in an experimental skeletal metastases model. *Cancer Res.* **62**, 3120–3125.
 78. Kerr C. 2002 ^{223}Ra targets skeletal metastases and spares normal tissue. *Lancet Oncol.* **3**, 453. (doi:10.1016/S1470-2045(02)00835-5)
 79. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. 2003 Targeting of osseous sites with α -emitting ^{223}Ra : comparison with the beta-emitter ^{89}Sr in mice. *J. Nucl. Med.* **44**, 252–259.
 80. Lewington VJ. 2005 Bone-seeking radionuclides for therapy. *J. Nucl. Med.* **46**, 385–475.
 81. Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland OS, Klastrop S, Harling R, Ramdahl T. 2006 Radiotoxicity of the alpha-emitting bone-seeker ^{223}Ra injected intravenously into mice: histology, clinical chemistry and hematology. *In Vivo* **20**, 325–331.
 82. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. 2005 First clinical experience with α -emitting radium-223 in the treatment of skeletal metastases. *Clin. Cancer Res.* **11**, 4451–4459. (doi:10.1158/1078-0432.CCR-04-2244)
 83. Nilsson S *et al.* 2007 Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. *Lancet Oncol.* **8**, 587–594. (doi:10.1016/S1470-2045(07)70147-X)
 84. Nilsson S *et al.* 2012 A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. *Eur. J. Cancer* **48**, 678–686. (doi:10.1016/j.ejca.2011.12.023)
 85. Pniok M, Kubíček V, Havlíčková J, Kotek J, Sabatie-Gogová A, Plutnar J, Huclier-Markai S, Hermann P. 2014 Thermodynamic and kinetic study of scandium(III) complexes of DTPA and DOTA: a step toward scandium radiopharmaceuticals. *Chem. Eur. J.* **20**, 7944–7955. (doi:10.1002/chem.201402041)
 86. Roesch F. 2012 Scandium-44: benefits of a long-lived PET radionuclide available from the $^{44}\text{Ti}/^{44}\text{Sc}$ generator system. *Curr. Radiopharm.* **5**, 187–201. (doi:10.2174/1874471011205030187)
 87. Müller C, Bunka M, Reber J, Fischer C, Zhernosekov K, Türler A, Schibli R. 2013 Promises of cyclotron-produced ^{44}Sc as a diagnostic match for trivalent β^- -emitters: *in vitro* and *in vivo* study of a ^{44}Sc -DOTA-folate conjugate. *J. Nucl. Med.* **54**, 2168–2174. (doi:10.2967/jnumed.113.123810)
 88. Schroeder HA, Balassa JJ, Vinton Jr WH. 1964 Chromium, lead, cadmium, nickel and titanium in mice: effect on mortality, tumors and tissue levels. *J. Nutr.* **83**, 239–250.
 89. Yaghoubi S, Schwietert CW, McCue JP. 2000 Biological roles of titanium. *Biol. Trace Elem. Res.* **78**, 205–217. (doi:10.1385/BTER:78:1-3:205)
 90. Schwietert CW, Yaghoubi S, Gerber NC, McSharry JJ, McCue JP. 2001 Dietary titanium and infant growth. *Biol. Trace Elem. Res.* **83**, 149–167. (doi:10.1385/BTER:83:2:149)
 91. Pais I, Ravasz MF, Nagy B, Bokori J, Szabo Z. 1984 *Fodder and fodder additives promoting the weight increase of domestic animals and a process for the use thereof*. US Patent 4482550 A.
 92. Buettner KM, Valentine AM. 2012 Bioinorganic chemistry of titanium. *Chem. Rev.* **112**, 1863–1881. (doi:10.1021/cr1002886)
 93. Abeyasinghe PM, Harding MM. 2007 Antitumor bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives. *Dalton Trans.* 3474–3482. (doi:10.1039/b707440a)
 94. Caruso F, Rossi M. 2004 Antitumor titanium compounds. *Mini Rev. Med. Chem.* **4**, 49–60. (doi:10.2174/1389557043487565)
 95. Sweeney NJ, Mendoza O, Müller-Bunz H, Pampillón C, Rehmann F-JK, Strohfeltdt K, Tacke M. 2005 Novel benzyl substituted titanocene anti-cancer drugs. *J. Organomet. Chem.* **690**, 4537–4544. (doi:10.1016/j.jorganchem.2005.06.039)
 96. Peri D, Meker S, Shavit M, Tshuva EY. 2009 Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C_2 - and C_1 -symmetrical Ti^{IV} complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents. *Chemistry* **15**, 2403–2415. (doi:10.1002/chem.200801310)

97. Schur J, Manna CM, Deally A, Köster RW, Tacke M, Tshuva EY, Ott I. 2013 A comparative chemical-biological evaluation of titanium(IV) complexes with a salan or cyclopentadienyl ligand. *Chem. Commun.* **49**, 4785–4787. (doi:10.1039/c3cc38604j)
98. Quist EE, Hokin LE. 1978 The presence of two ($\text{Na}^+ + \text{K}^+$)-ATPase inhibitors in equine muscle ATP: vanadate and a dithioerythritol-dependent inhibitor. *Biochim. Biophys. Acta* **511**, 202–212. (doi:10.1016/0005-2736(78)90314-0)
99. Rehder D. 2013 Vanadium. Its role for humans. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 139–169. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
100. Thompson KH, Orvig C. 2006 Metal complexes in medicinal chemistry: new vistas and challenges in drug design. *Dalton Trans.* 761–764. (doi:10.1039/b513476e)
101. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. 2009 Vanadium treatment of type 2 diabetes: a view to the future. *J. Inorg. Biochem.* **103**, 554–558. (doi:10.1016/j.jinorgbio.2008.12.003)
102. Rehder D. 2012 The potentiality of vanadium in medicinal applications. *Future Med. Chem.* **4**, 1823–1837. (doi:10.4155/fmc.12.103)
103. Schwarz K, Mertz W. 1959 Chromium(III) and the glucose tolerance factor. *Arch. Biochem. Biophys.* **85**, 292–295. (doi:10.1016/0003-9861(59)90479-5)
104. Avila DS, Puntel RL, Aschner M. 2013 Manganese in health and disease. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 199–227. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
105. Vincent JB. 2013 Chromium: is it essential, pharmacologically relevant, or toxic? In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 171–198. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
106. Martinez-Finley EJ, Gavin CE, Aschner M, Gunter TE. 2013 Manganese neurotoxicity and the role of reactive oxygen species. *Free Radic. Biol. Med.* **62**, 65–75. (doi:10.1016/j.freeradbiomed.2013.01.032)
107. London RE, Toney G, Gabel SA, Funk A. 1989 Magnetic resonance imaging studies of the brains of anesthetized rats treated with manganese chloride. *Brain Res. Bull.* **23**, 229–235. (doi:10.1016/0361-9230(89)90152-4)
108. Foradori AC, Bertinchamps A, Gulibon JM, Cotzias GC. 1967 Discrimination between magnesium and manganese by serum proteins. *J. Gen. Physiol.* **50**, 2255–2266. (doi:10.1085/jgp.50.9.2255)
109. Takeda A, Akiyama T, Sawashita J, Okada S. 1994 Brain uptake of trace metals, zinc and manganese, in rats. *Brain Res.* **640**, 341–344. (doi:10.1016/0006-8993(94)91891-0)
110. Fitsanakis VA, Piccola G, dos Santos AP, Marreilha A, Judy L, Aschner M. 2007 Putative proteins involved in manganese transport across the blood-brain barrier. *Hum. Exp. Toxicol.* **26**, 295–302. (doi:10.1177/0960327107070496)
111. Crichton RR. 2009 *Iron metabolism—from molecular mechanisms to clinical consequences*, 3rd edn. Chichester, UK: Wiley.
112. Andreini C, Bertini I, Rosato A. 2009 Metalloproteomes: a bioinformatic approach. *Acc. Chem. Res.* **42**, 1471–1479. (doi:10.1021/ar900015x)
113. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, Balla G. 2003 Haem, haem oxygenase and ferritin in vascular endothelial cell injury. *Nephrol. Dial. Transplant.* **18**, v8–v12. (doi:10.1093/ndt/gfg1034)
114. Hider RC, Kong X. 2013 Iron: effect of overload and deficiency. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 229–294. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
115. Johnson MK, Smith AD. 2011 Iron–sulfur proteins. In *Encyclopedia of inorganic and bioinorganic chemistry*. Hoboken, NJ: Wiley. (doi:10.1002/9781119951438.eibc0109)
116. Beinert H. 2000 Iron–sulfur proteins: ancient structures, still full of surprises. *J. Biol. Inorg. Chem.* **5**, 2–15. (doi:10.1007/s007750050002)
117. Cook JD, Reddy MB, Burri J, Juillerat MA, Hurrell RF. 1997 The influence of different cereal grains on iron absorption from infant cereal foods. *Am. J. Clin. Nutr.* **65**, 964–969.
118. Chen W *et al.* 2009 Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. *Proc. Natl Acad. Sci. USA* **106**, 16 263–16 268. (doi:10.1073/pnas.0904519106)
119. A comparative safety and activity study with ferroquine associated with artesunate versus amodiaquine associated with artesunate in African adult patients with uncomplicated

- malaria. See <http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00563914> (accessed: 10 November 2014).
120. Dubar F, Khalife J, Brocard J, Dive D, Biot C. 2008 Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action. *Molecules* **13**, 2900–2907. (doi:10.3390/molecules13112900)
 121. Top S, Vessières A, Leclercq G, Quivy J, Tang J, Vaissermann J, Huché M, Jaouen G. 2003 Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. *Chem. Eur. J.* **9**, 5223–5236. (doi:10.1002/chem.200305024)
 122. Wang YX. 2011 Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. *Quant. Imaging Med. Surg.* **1**, 35–40. (doi:10.3978/j.issn.2223-4292.2011.08.03)
 123. Friederich JA, Butterworth JF. 1995 Sodium nitroprusside: twenty years and counting. *Anesth. Analg.* **81**, 152–162. (doi:10.1213/00000539-199507000-00031)
 124. Yamada K. 2013 Cobalt: its role in health and disease. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 295–320. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
 125. Kozyraki R, Cases O. 2013 Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. *Biochimie* **85**, 1002–1007. (doi:10.1016/j.biochi.2012.11.004)
 126. Mathews FS, Gordon MM, Chen Z, Rajashankar KR, Ealick SE, Alpers DH, Sukumar N. 2007 Crystal structure of human intrinsic factor: cobalamin complex at 2.6-Å resolution. *Proc. Natl Acad. Sci. USA* **104**, 17311–17316. (doi:10.1073/pnas.0703228104)
 127. Epstein S, Pashinsky Y, Gershon D, Winicov I, Srivilasa C, Kristic K, Asbell P. 2006 Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. *BMC Ophthalmol.* **6**, 22. (doi:10.1186/1471-2415-6-22)
 128. Zambelli B, Ciurli S. 2013 Nickel and human health. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 322–358. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
 129. Desguin B, Goffin P, Viaene E, Kleerebezem M, Martin-Diaconescu V, Maroney MJ, Declercq JP, Soumillion P, Hols P. 2014 Lactate racemase is a nickel-dependent enzyme activated by a widespread maturation system. *Nat. Commun.* **5**, 3615. (doi:10.1038/ncomms4615)
 130. de Reuse H, Vinella D, Cavazza C. 2013 Common themes and unique proteins for the uptake and trafficking of nickel, a metal essential for the virulence of *Helicobacter pylori*. *Front. Cell. Infect. Microbiol.* **3**, 94. (doi:10.3389/fcimb.2013.00094)
 131. Vollmer J, Weltzien HU, Gamerdinger K, Lang S, Choleva Y, Moulon C. 2000 Antigen contacts by Ni-reactive TCR: typical alpha chain cooperation versus alpha chain-dominated specificity. *Int. Immunol.* **12**, 1723–1731. (doi:10.1093/intimm/12.12.1723)
 132. Linder MC. 1991 *The biochemistry of copper*. New York, NY: Plenum Press.
 133. Andreini C, Banci L, Bertini I, Rosato A. 2008 Occurrence of copper proteins through the three domains of life: a bioinformatic approach. *J. Proteome Res.* **7**, 209–216. (doi:10.1021/pr070480u)
 134. Scheiber I, Dringen R, Mercer JFB. 2013 Copper: effects of deficiency and overload. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 359–387. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
 135. Kaim W, Rall J. 1996 Copper—a ‘modern’ bioelement. *Angew. Chem. Int. Ed. Engl.* **35**, 43–60. (doi:10.1002/anie.199600431)
 136. Kosman DJ. 2010 Multicopper oxidases: a workshop on copper coordination chemistry, electron transfer, and metallophysiology. *J. Biol. Inorg. Chem.* **15**, 15–28. (doi:10.1007/s00775-009-0590-9)
 137. Gaggelli E, Kozlowski H, Valensin D, Valensin G. 2006 Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). *Chem. Rev.* **106**, 1995–2044. (doi:10.1021/cr040410w)
 138. Andreini C, Banci L, Bertini I, Rosato A. 2006 Counting the zinc-proteins encoded in the human genome. *J. Proteome Res.* **5**, 196–201. (doi:10.1021/pr050361j)
 139. Auld DS. 2001 Zinc coordination sphere in biochemical zinc sites. *BioMetals* **14**, 271–313. (doi:10.1023/a:1012976615056)

140. Maret W. 2013 Zinc and human disease. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 389–414. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
141. Albrecht U, Eichele G. 2003 The mammalian circadian clock. *Curr. Opin. Genet. Dev.* **13**, 271–277. (doi:10.1016/S0959-437X(03)00055-8)
142. Schmalen I, Reischl S, Wallach T, Klemz R, Grudziecki A, Prabu JR, Benda C, Kramer A, Wolf E. 2014 Interaction of circadian clock proteins CRY1 and PER2 is modulated by zinc binding and disulfide bond formation. *Cell* **157**, 1203–1215. (doi:10.1016/j.cell.2014.03.057)
143. Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. 2011 Yttrium-90 (⁹⁰Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). *Crit. Rev. Oncol. Hematol.* **80**, 393–410. (doi:10.1016/j.critrevonc.2011.01.012)
144. Huang J, Cui L, Wang F, Liu Z. 2011 PET tracers based on ⁸⁶Y. *Curr. Radiopharm.* **4**, 122–130. (doi:10.2174/1874471011104020122)
145. Schroeder HA, Balassa JJ. 1966 Abnormal trace materials in man: zirconium. *J. Chronic Dis.* **19**, 573–586. (doi:10.1016/0021-9681(66)90095-6)
146. Lee DB, Roberts M, Bluchel CG, Odell RA. 2010 Zirconium: biomedical and nephrological applications. *ASAIO J.* **56**, 550–556. (doi:10.1097/MAT.0b013e3181e73f20)
147. Chang PP, Henegbarth EA, Lang LA. 2007 Maxillary zirconia implant fixed partial dentures opposing an acrylic resin implant fixed complete denture: a two-year clinical report. *J. Prosthet. Dent.* **97**, 321–330. (doi:10.1016/S0022-3913(07)60020-1)
148. Vigolo P, Fonzi F. 2008 An *in vitro* evaluation of fit of zirconium-oxide-based ceramic four-unit fixed partial dentures, generated with three different CAD/CAM systems, before and after porcelain firing cycles and after glaze cycles. *J. Prosthodont.* **17**, 621–626. (doi:10.1111/j.1532-849X.2008.00366.x)
149. Garvin KL, Hartman CW, Mangla J, Murdoch N, Martell JM. 2009 Wear analysis in THA utilizing oxidized zirconium and crosslinked polyethylene. *Clin. Orthop. Relat. Res.* **467**, 141–145. (doi:10.1007/s11999-008-0544-5)
150. Schadel A, Thun G, Stork L, Metzler R. 1993 Immunodiffusion and immunohistochemical investigations on the reactivity of oxide ceramic middle-ear implants. *ORL J. Otorhinolaryngol. Relat. Spec.* **55**, 216–221. (doi:10.1159/000276426)
151. Laden K. 1988 Introduction and history of antiperspirants and deodorants. In *Antiperspirants and deodorants* (eds K Laden, CB Felger), pp. 1–13. New York, NY: Marcel Decker.
152. Zhang H *et al.* 2012 Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus. *Bioorg. Med. Chem. Lett.* **22**, 1664–1669. (doi:10.1016/j.bmcl.2011.12.115)
153. Schwarz G, Belaidi AA. 2013 Molybdenum in human health and disease. In *Interrelations between essential metal ions and human diseases* (eds RKO Sigel, A Sigel, H Sigel), pp. 415–450. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
154. Burguera JL, Burguera M. 2007 Molybdenum in human whole blood of adult residents of the Merida State (Venezuela). *J. Trace Elem. Med. Biol.* **21**, 178–183. (doi:10.1016/j.jtemb.2007.03.005)
155. Kuper J, Llamas A, Hecht HJ, Mendel RR, Schwarz G. 2004 Structure of the molybdopterin-bound Cnx1G domain links molybdenum and copper metabolism. *Nature* **430**, 803–806. (doi:10.1038/nature02681)
156. Schwarz G, Mendel RR, Ribbe MW. 2009 Molybdenum cofactors, enzymes and pathways. *Nature* **460**, 839–847. (doi:10.1038/nature08302)
157. Panneerselvam SR, Govindasamy S. 2004 Effect of sodium molybdate on the status of lipids, lipid peroxidation and antioxidant systems in alloxan-induced diabetic rats. *Clin. Chim. Acta* **345**, 93–98. (doi:10.1016/j.cccn.2004.03.005)
158. Suttle NF. 2012 Copper imbalances in ruminants and humans: unexpected common ground. *Adv. Nutr.* **3**, 666–674. (doi:10.3945/an.112.002220)
159. Zolle I (ed). 2007 *Technetium-99m pharmaceuticals: preparation and quality control in nuclear medicine*. Berlin, Germany: Springer.
160. Barry NP, Sadler PJ. 2013 Exploration of the medical periodic table: towards new targets. *Chem. Commun.* **49**, 5106–5131. (doi:10.1039/c3cc41143e)

161. Cocchietto M, Zorzet S, Sorc A, Sava G. 2003 Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration. *Invest. New Drugs* **21**, 55–62. (doi:10.1023/A:1022916310694)
162. Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. 2013 ^{99m}Tc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. *J. Nucl. Med.* **54**, 1369–1376. (doi:10.2967/jnumed.112.116624)
163. Sava G *et al.* 2003 Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. *Clin. Cancer Res.* **9**, 1898–1905.
164. Bratsos I, Jedner S, Gianferrara T, Alessio E. 2007 Ruthenium anticancer compounds: challenges and expectations. *Chimia* **61**, 692–697. (doi:10.2533/chimia.2007.692)
165. Bergamo A, Sava G. 2007 Ruthenium complexes can target determinants of tumour malignancy. *Dalton Trans.* 1267–1272. (doi:10.1039/B617769G)
166. Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G. 1998 Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. *Clin. Exp. Metastasis* **16**, 371–379. (doi:10.1023/A:1006521715400)
167. Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G. 2012 Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. *J. Inorg. Biochem.* **106**, 90–99. (doi:10.1016/j.jinorgbio.2011.09.030)
168. Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, Keppler BK. 2008 KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients. *Chem. Biodivers.* **5**, 2140–2155. (doi:10.1002/cbdv.200890195)
169. Lentz F *et al.* 2009 Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. *Anticancer Drugs* **20**, 97–103. (doi:10.1097/CAD.0b013e3283222fbc5)
170. Yan YK, Melchart M, Habtemariam A, Sadler PJ. 2005 Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. *Chem. Commun.* 4764–4776. (doi:10.1039/B508531B)
171. Fricker SP. 1999 Nitric oxide scavengers as a therapeutic approach to nitric oxide mediated disease. *Expert Opin. Investig. Drugs* **8**, 1209–1222. (doi:10.1517/13543784.8.8.1209)
172. Chellan P, Land KM, Shokar A, Au A, An SH, Taylor D, Smith PJ, Chibale K, Smith GS. 2013 Di- and trinuclear ruthenium-, rhodium-, and iridium-functionalized pyridyl aromatic ethers: a new class of antiparasitic agents. *Organometallics* **32**, 4793–4804. (doi:10.1021/om400493k)
173. Simpson PV, Schmidt C, Ott I, Bruhn H, Schatzschneider U. 2013 Synthesis, cellular uptake and biological activity against pathogenic microorganisms and cancer cells of rhodium and iridium N-heterocyclic carbene complexes bearing charged substituents. *Eur. J. Inorg. Chem.* 5547–5554. (doi:10.1002/ejic.201300820)
174. Menon EL, Perera R, Navarro M, Kuhn RJ, Morrison H. 2004 Phototoxicity against tumor cells and sindbis virus by an octahedral rhodium bisbipyridyl complex and evidence for the genome as a target in viral photoinactivation. *Inorg. Chem.* **43**, 5373–5381. (doi:10.1021/ic0498586)
175. Geldmacher Y, Oleszak M, Sheldrick WS. 2012 Rhodium(III) and iridium(III) complexes as anticancer agents. *Inorg. Chim. Acta* **393**, 84–102. (doi:10.1016/j.ica.2012.06.046)
176. Ando A, Ando I, Tonami N, Kinuya S, Okamoto N, Sugimoto M, Fukuda N, Matsumoto S. 2000 Production of ¹⁰⁵Rh-EDTMP and its bone accumulation. *Appl. Radiat. Isot.* **52**, 211–215. (doi:10.1016/S0969-8043(99)00129-3)
177. Brun PM, Bucking M, DeGroot JL, Farahani M, Pottier RH. 2004 Neutron activation and liquid scintillation analysis of tissue samples containing palladium bacteriochlorophyll derivative, a potential photochemotherapeutic agent. *Can. J. Anal. Sci. Spectrosc.* **49**, 55–63. (doi:10.1016/j.brachy.2013.04.001)
178. Vascular targeted photodynamic therapy T1a renal tumours (KCM201). See <http://clinicaltrials.gov/ct2/show/NCT01573156> (accessed 10 November 2014).
179. Taylor JM. 1989 Use of sources for brachytherapy. *Fed. Regist.* **54**, 41 819–41 821.
180. Finger PT, Berson A, Ng T, Szechter A. 2002 Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. *Int. J. Radiat. Oncol. Biol. Phys.* **54**, 1438–1445. (doi:10.1016/S0360-3016(02)03751-3)

181. Pd-103 dose de-escalation for early stage prostate cancer: a prospective randomized trial. See <http://clinicaltrials.gov/ct2/show/NCT00247312> (accessed 10 November 2014).
182. High versus low dose supplemental external radiation with Pd-103 for prostate cancer. See <http://clinicaltrials.gov/ct2/show/NCT00494546> (accessed 10 November 2014).
183. Chopra I. 2007 The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? *J. Antimicrob. Chemother.* **59**, 587–590. (doi:10.1093/jac/dkm006)
184. Klases HJ. 2000 Historical review of the use of silver in the treatment of burns. I. Early uses. *Burns* **26**, 117–130. (doi:10.1016/S0305-4179(99)00108-4)
185. Leaper DJ. 2006 Silver dressings: their role in wound management. *Int. Wound J.* **3**, 282–294. (doi:10.1111/j.1742-481X.2006.00265.x)
186. Fox Jr CL. 1968 Silver sulfadiazine—a new topical therapy for *Pseudomonas* in burns. Therapy of *Pseudomonas* infection in burns. *Arch. Surg.* **96**, 184–188. (doi:10.1001/archsurg.1968.01330200022004)
187. George N, Faoagali J, Muller M. 1997 Silvazine (silver sulfadiazine and chlorhexidine) activity against 200 clinical isolates. *Burns* **23**, 493–495. (doi:10.1016/S0305-4179(97)00047-8)
188. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. 2006 Guidelines for the prophylaxis and treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the UK. *J. Antimicrob. Chemother.* **57**, 589–608. (doi:10.1093/jac/dkl017)
189. Clinical trial of a Silver Eluting Dressing System (SILVER). See <https://clinicaltrials.gov/ct2/show/NCT01229358> (accessed 10 November 2014).
190. Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M. 2011 Silver nanoparticles as potential antiviral agents. *Molecules* **16**, 8894–8918. (doi:10.3390/molecules16108894)
191. Soumya RS, Hela PG. 2013 Nano silver based targeted drug delivery for treatment of cancer. *Der Pharmacia Lettre* **5**, 189–197.
192. Iqbal J, Barsukova-Stuckart M, Ibrahim M, Ali S, Khan A, Kortz U. 2013 Polyoxometalates as potent inhibitors for acetyl and butyrylcholinesterases and as potential drugs for the treatment of Alzheimer's disease. *Med. Chem. Res.* **22**, 1224–1228. (doi:10.1007/s00044-012-0125-8)
193. Suzuki CA, Ohta H, Albores A, Koropatnick J, Cherian MG. 1990 Induction of metallothionein synthesis by zinc in cadmium pretreated rats. *Toxicology* **63**, 273–284. (doi:10.1016/0300-483X(90)90190-R)
194. Xu Y, Feng L, Jeffrey PD, Shi Y, Morel FM. 2008 Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. *Nature* **452**, 56–61. (doi:10.1038/nature06636)
195. Maggiorella L, Barouch G, Devaux C, Pottier A, Deutsch E, Bourhis J, Borghi E, Levy L. 2012 Nanoscale radiotherapy with hafnium oxide nanoparticles. *Future Oncol.* **8**, 1167–1181. (doi:10.2217/fon.12.96)
196. Marill J, Anesary NM, Zhang P, Vivet S, Borghi E, Levy L, Pottier A. 2014 Hafnium oxide nanoparticles: toward an *in vitro* predictive biological effect? *Radiat. Oncol.* **9**, 150. (doi:10.1186/1748-717X-9-150)
197. Pottier A, Borghi E, Levy L. 2014 New use of metals as nanosized radioenhancers. *Anticancer Res.* **34**, 443–453.
198. Bermudez MD, Carrion FJ, Martinez-Nicolas G, Lopez R. 2005 Erosion-corrosion of stainless steels, titanium, tantalum and zirconium. *Wear* **258**, 693–700. (doi:10.1016/j.wear.2004.09.023)
199. Kato H, Nakamura T, Nishiguchi S, Matsusue Y, Kobayashi M, Miyazaki T, Kim H, Kokubo T. 2000 Bonding of alkali- and heat-treated tantalum implants to bone. *J. Biomed. Mater. Res.* **53**, 28–35. (doi:10.1002/(SICI)1097-4636(2000)53:1<28::AID-JBM4>3.0.CO;2-F)
200. Zardiackas LD, Parsell DE, Dillon LD, Mitchell DW, Nunnery LA, Poggie R. 2001 Structure, metallurgy, and mechanical properties of a porous tantalum foam. *J. Biomed. Mater. Res. Appl. Biomater.* **58**, 180–187. (doi:10.1002/1097-4636(2001)58:2<180::AID-JBM1005>3.0.CO;2-5)
201. Bobynd JD, Stackpool GJ, Hacking SA, Tanzer M, Krygier JJ. 1999 Characteristics of bone ingrowth and interface mechanics of a new porous tantalum biomaterial. *J. Bone Joint Surg. Br.* **81**, 907–914. (doi:10.1302/0301-620X.81B5.9283)
202. Hacking SA, Bobynd JD, Toh K, Tanzer M, Krygier JJ. 2000 Fibrous tissue ingrowth and attachment to porous tantalum. *J. Biomed. Mater. Res.* **52**, 631–638. (doi:10.1002/1097-4636(20001215)52:4<631::AID-JBM7>3.0.CO;2-6)
203. Domingo JL. 2002 Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. *Biol. Trace Elem. Res.* **88**, 97–113. (doi:10.1385/BTER:88:2:097)

204. Muñoz MC, Barberà A, Domínguez J, Fernández-Alvarez J, Gomis R, Guinovart JJ. 2001 Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats. *Diabetes* **50**, 131–138. (doi:10.2337/diabetes.50.1.131)
205. Barberà A, Fernández-Alvarez J, Truc A, Gomis R, Guinovart JJ. 1997 Effects of tungstate in neonatally streptozotocin-induced diabetic rats: mechanism leading to normalization of glycaemia. *Diabetologia* **40**, 143–149. (doi:10.1007/s001250050655)
206. Barberà A, Gomis RR, Prats N, Rodríguez-Gil JE, Domingo M, Gomis R, Guinovart JJ. 2001 Tungstate is an effective antidiabetic agent in streptozotocin-induced diabetic rats: a long-term study. *Diabetologia* **44**, 507–513. (doi:10.1007/s001250100479)
207. Barberà A, Rodríguez-Gil JE, Guinovart JJ. 1994 Insulin-like actions of tungstate in diabetic rats. Normalization of hepatic glucose metabolism. *J. Biol. Chem.* **269**, 20 047–20 053.
208. Domínguez JE *et al.* 2003 The antidiabetic agent sodium tungstate activates glycogen synthesis through an insulin receptor-independent pathway. *J. Biol. Chem.* **278**, 42 785–42 794. (doi:10.1074/jbc.M308334200)
209. Stiefel EI. 1998 Transition metal sulfur chemistry and its relevance to molybdenum and tungsten enzymes. *Pure Appl. Chem.* **70**, 889–896. (doi:10.1351/pac199870040889)
210. Khangulov SV, Gladyshev VN, Dismukes GC, Stadtman TC. 1998 Selenium-containing formate dehydrogenase H from *Escherichia coli*: a molybdopterin enzyme that catalyzes formate oxidation without oxygen transfer. *Biochemistry* **37**, 3518–3528. (doi:10.1021/bi972177k)
211. Fukuma M, Seto Y, Yamase T. 1991 In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus. *Antiviral Res.* **16**, 327–339. (doi:10.1016/0166-3542(91)90047-U)
212. Inoue M, Segawa K, Matsunaga S, Matsumoto N, Oda M, Yamase T. 2005 Antibacterial activity of highly negative charged polyoxotungstates, $K_{27}[KAs_4W_{40}O_{140}]$ and $K_{18}[KSb_9W_{21}O_{86}]$, and Keggin-structural polyoxotungstates against *Helicobacter pylori*. *J. Inorg. Biochem.* **99**, 1023–1031. (doi:10.1016/j.jinorgbio.2005.01.010)
213. Wang L, Zhou B-B, Yu K, Su Z-H, Gao S, Chu L-L, Liu J-R, Yang G-Y. 2013 Novel antitumor agent, trilacunary Keggin-type tungstobismuthate, inhibits proliferation and induces apoptosis in human gastric cancer SGC-7901 cells. *Inorg. Chem.* **52**, 5119–5127. (doi:10.1021/ic400019r)
214. Deutsch E, Brodack JW, Deutsch KF. 1993 Radiation synovectomy revisited. *Eur. J. Nucl. Med.* **20**, 1113–1127. (doi:10.1007/BF00173494)
215. Lambert B, de Klerk JM. 2006 Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. *Nucl. Med. Commun.* **27**, 223–229. (doi:10.1097/00006231-200603000-00004)
216. Phase I/II trial of rhenium 188-P2045 in small cell lung cancer and other advanced neuroendocrine carcinomas. See <https://clinicaltrials.gov/ct2/show/NCT02030184>. (accessed 10 November 2014).
217. Edelman MJ, Clamon G, Kahn D, Magram M, Lister-James J, Line BR. 2009 Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. *J. Thorac. Oncol.* **4**, 1550–1554. (doi:10.1097/JTO.0b013e3181bf1070)
218. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. 1994 Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. *Life Sci.* **55**, 1797–1806. (doi:10.1016/0024-3205(94)90090-6)
219. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. 2001 Somatostatin, its receptor and analogs in lung cancer. *Chemotherapy* **47**, 78–108. (doi:10.1159/000049163)
220. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L, Abrahamsson PA. 2002 Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. *Urol. Oncol.* **7**, 91–98. (doi:10.1016/S1078-1439(01)00173-9)
221. Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S. 2005 Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. *Breast Cancer Res. Treat.* **92**, 175–186. (doi:10.1007/s10549-005-2414-0)
222. Berglof FE. 1959 Osmic acid in arthritis therapy. *Acta Rheumatol. Scand.* **5**, 70–74. (doi:10.3109/rhe1.1959.5.issue-1-4.11)

223. Bessant R, Steuer A, Rigby S, Gumpel M. 2003 Osmic acid revisited: factors that predict a favourable response. *Rheumatology* **42**, 1036–1043. (doi:10.1093/rheumatology/keg283)
224. Goldstein S, Czapski G, Heller A. 2005 Osmium tetroxide, used in the treatment of arthritic joints, is a fast mimic of superoxide dismutase. *Free Radic. Biol. Med.* **38**, 839–845. (doi:10.1016/j.freeradbiomed.2004.10.027)
225. Noffke AL, Habtemariam A, Pizarro AM, Sadler PJ. 2012 Designing organometallic compounds for catalysis and therapy. *Chem. Commun.* **48**, 5219–5246. (doi:10.1039/c2cc30678f)
226. Radical radiotherapy by external beam radiation versus radical radiotherapy with temporary iridium implant plus external beam radiation in carcinoma of the prostate. See <https://clinicaltrials.gov/ct2/show/NCT00548600>.
227. A multicenter trial of localized radiation therapy to inhibit restenosis (GAMMA V). See <https://clinicaltrials.gov/ct2/show/record/NCT00232778> (accessed 10 November 2014).
228. Leung C-H, Zhong H-J, Chan DS-H, Ma D-L. 2013 Bioactive iridium and rhodium complexes as therapeutic agents. *Coord. Chem. Rev.* **257**, 1764–1776. (doi:10.1016/j.ccr.2013.01.034)
229. Li SP-Y, Lau CT-S, Louie M-W, Lam Y-W, Cheng SH, Lo KK-W. 2013 Mitochondria-targeting cyclometalated iridium(III)–PEG complexes with tunable photodynamic activity. *Biomaterials* **34**, 7519–7532. (doi:10.1016/j.biomaterials.2013.06.028)
230. Flamigni L, Barbieri A, Sabatini C, Ventura B, Barigelletti F. 2007 Photochemistry and photophysics of coordination compounds: iridium. In *Photochemistry and photophysics of coordination compounds II* (eds V Balzani, S Campagna), pp. 143–203. Berlin, Germany: Springer.
231. Liu Z, Sadler PJ. 2014 Organoiridium complexes: anticancer agents and catalysts. *Acc. Chem. Res.* **47**, 1174–1185. (doi:10.1021/ar400266c)
232. Wheate NJ, Walker S, Craig GE, Oun R. 2010 The status of platinum anticancer drugs in the clinic and in clinical trials. *Dalton Trans.* **39**, 8113–8127. (doi:10.1039/c0dt00292e)
233. Gabano E, Ravera M, Osella D. 2014 Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one. *Dalton Trans.* **43**, 9813–9820. (doi:10.1039/C4DT00911H)
234. Stathopoulos GP *et al.* 2010 Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. *Ann. Oncol.* **21**, 2227–2232. (doi:10.1093/annonc/mdq234)
235. Stathopoulos GP, Boulikas T. 2012 Lipoplatin formulation review article. *J. Drug Deliv.* **581363**. (doi:10.1155/2012/581363)
236. Farrel NP. 2004 Polynuclear platinum drugs. In *Metal ions in biological systems: metal complexes in tumor diagnosis and as anticancer agents* (ed. H Sigel), pp. 251–296. Dordrecht, The Netherlands: Springer.
237. Butler JS, Sadler PJ. 2013 Targeted delivery of platinum-based anticancer complexes. *Curr. Opin. Chem. Biol.* **17**, 175–188. (doi:10.1016/j.cbpa.2013.01.004)
238. Muhammad N, Guo Z. 2014 Metal-based anticancer chemotherapeutic agents. *Curr. Opin. Chem. Biol.* **19**, 144–153. (doi:10.1016/j.cbpa.2014.02.003)
239. Todd RC, Lippard SJ. 2009 Inhibition of transcription by platinum antitumor compounds. *Metallomics* **1**, 280–291. (doi:10.1039/b907567d)
240. Safaei R, Howell SB. 2005 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. *Crit. Rev. Oncol. Hematol.* **53**, 13–23. (doi:10.1016/j.critrevonc.2004.09.007)
241. Pizarro AM, McQuitty RJ, Mackay FS, Zhao Y, Woods JA, Sadler PJ. 2014 Cellular accumulation, lipophilicity and photocytotoxicity of diazido platinum(IV) anticancer complexes. *ChemMedChem* **9**, 1169–1175. (doi:10.1002/cmdc.201402066)
242. Farrer NJ, Sadler PJ. 2008 Photochemotherapy: targeted activation of metal anticancer complexes. *Aust. J. Chem.* **61**, 669–674. (doi:10.1071/CH08088)
243. Aryal S, Hu C-MJ, Zhang L. 2009 Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery. *ACS Nano* **4**, 251–258. (doi:10.1021/nn9014032)
244. Raubenheimer HG, Schmidbaur H. 2014 The late start and amazing upswing in gold chemistry. *J. Chem. Educ.* **91**, 2024–2036. (doi:10.1021/ed400782p)
245. Bertini I, Gray HB, Lippard SJ, Valentine JS. 1994 *Bioinorganic chemistry*. Mill Valley, CA: University Science Books.

246. PKC α & mTOR inhibition with auranofin+sirolimus for squamous cell lung cancer. See <https://clinicaltrials.gov/ct2/show/NCT01737502> (accessed 10 November 2014).
247. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. 2006 Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. *Science* **312**, 1027–1030. (doi:10.1126/science.1125559)
248. Zhang D, Liu D, Zhang J, Fong C, Yang M. 2014 Gold nanoparticles stimulate differentiation and mineralization of primary osteoblasts through the ERK/MAPK signaling pathway. *Mater. Sci. Eng. C* **42**, 70–77. (doi:10.1016/j.msec.2014.04.042)
249. Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ. 2009 Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. *J. Am. Chem. Soc.* **131**, 14 652–14 653. (doi:10.1021/ja9071282)
250. El-Sayed IH, Huang X, El-Sayed MA. 2005 Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. *Nano Lett.* **5**, 829–834. (doi:10.1021/nl050074e)
251. Debnath A *et al.* 2012 A high-throughput drug screen for *Entamoeba histolytica* identifies a new lead and target. *Nat. Med.* **18**, 956–960. (doi:10.1038/nm.2758)
252. Masur LC. 2011 A review of the use of mercury in historic and current ritualistic and spiritual practices. *Altern. Med. Rev.* **16**, 314–320.
253. Ball LK, Ball R, Pratt RD. 2001 An assessment of thimerosal use in childhood vaccines. *Pediatrics* **107**, 1147–1154. (doi:10.1542/peds.107.5.1147)
254. Baker JP. 2008 Mercury, vaccines, and autism one controversy, three histories. *Am. J. Public Health* **98**, 244–253. (doi:10.2105/AJPH.2007.113159)
255. Parker SK, Schwartz B, Todd J, Pickering LK. 2004 Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. *Pediatrics* **114**, 793–804. (doi:10.1542/peds.2004-0434)
256. Xu J *et al.* 2013 Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. *BMC Nephrol.* **14**, 29. (doi:10.1186/1471-2369-14-29)
257. Kalaitzidis RG, Elisaf MS. 2014 Hyperphosphatemia and phosphate binders: effectiveness and safety. *Curr. Med. Res. Opin.* **30**, 109–112. (doi:10.1185/03007995.2013.841667)
258. Drüeke TB. 2007 Phosphorus metabolism and management in chronic kidney disease: lanthanum carbonate as a first-line phosphate binder: the ‘cons’. *Semin. Dial.* **20**, 329–332. (doi:10.1111/j.1525-139X.2007.00299.x)
259. Rambeck WA, Wehr U. 2000 Rare earth elements as alternative growth promoters in pig production. *Arch. Tierernähr.* **53**, 323–334. (doi:10.1080/17450390009381956)
260. Thacker P. 2013 Alternatives to antibiotics as growth promoters for use in swine production: a review. *J. Anim. Sci. Biotechnol.* **4**, 35. (doi:10.1186/2049-1891-4-35)
261. Sobek JM, Talburt DE. 1968 Effects of the rare earth cerium on *Escherichia coli*. *J. Bacteriol.* **95**, 47–51.
262. Boeckx W, Blondeel PN, Vandersteen K, De Wolf-Peeters C, Schmitz A. 1992 Effect of cerium nitrate-silver sulphadiazine on deep dermal burns: a histological hypothesis. *Burns* **18**, 456–462. (doi:10.1016/0305-4179(92)90177-V)
263. Monafo WW, Tandon SN, Ayvazian VH, Tuchschildt J, Skinner AM, Deitz F. 1976 Cerium nitrate: a new topical antiseptic for extensive burns. *Surgery* **80**, 465–473.
264. Peterson VM, Hansbrough JF, Wang XW, Zapata-Sirvent R, Boswick Jr JA. 1985 Topical cerium nitrate prevents postburn immunosuppression. *J. Trauma* **25**, 1039–1044. (doi:10.1097/00005373-198505000-00007)
265. Garner JP, Heppell PSJ. 2005 Cerium nitrate in the management of burns. *Burns* **31**, 539–547. (doi:10.1016/j.burns.2005.01.014)
266. Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C, Correa-Hernández L. 2014 ¹⁵³Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. *Arch. Med. Res.* **45**, 301–308. (doi:10.1016/j.arcmed.2014.03.006)
267. Vigna L, Matheoud R, Ridone S, Arginelli D, Della Monica P, Rudoni M, Inglese E, Brambilla M. 2011 Characterization of the [¹⁵³Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis. *Phys. Med.* **27**, 144–152. (doi:10.1016/j.ejmp.2010.08.001)

268. Serafini AN. 2000 Samarium Sm-153 leixidronam for the palliation of bone pain associated with metastases. *Cancer* **88**, 2934–2939. (doi:10.1002/1097-0142(20000615)88:12+<2934::AID-CNCR9>3.0.CO;2-S)
269. Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA. 2008 Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. *Eur. J. Nucl. Med. Mol. Imaging* **35**, 756–765. (doi:10.1007/s00259-007-0659-z)
270. Parlak Y, Gumuser G, Sayit E. In press. Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients. *Radiat. Prot. Dosimetry*. (doi:10.1093/rpd/ncu237)
271. Bartlett ML, Webb M, Durrant S, Morton JA, Allison R, Macfarlane DJ. 2002 Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. *Eur. J. Nucl. Med. Mol. Imaging* **29**, 1470–1477. (doi:10.1007/s00259-002-0934-y)
272. Maini CL, Bergomi S, Romano L, Sciuto R. 2004 153Sm-EDTMP for bone pain palliation in skeletal metastases. *Eur. J. Nucl. Med. Mol. Imaging* **31**, S171–S178. (doi:10.1007/s00259-004-1540-y)
273. Combination of external beam radiotherapy with 153Sm-EDTMP to treat high risk osteosarcoma. See <http://clinicaltrials.gov/ct2/show/NCT01886105> (accessed 10 November 2014).
274. Sm-EDTMP and autologous peripheral blood stem cell transplantation for breast cancer patients with bone only metastases. See <http://clinicaltrials.gov/ct2/show/NCT00429507> (accessed 10 November 2014).
275. Samarium Sm 153 leixidronam pentasodium combined with zoledronic acid or pamidronate in treating patients with relapsed or refractory multiple myeloma and bone pain. See <http://clinicaltrials.gov/ct2/show/NCT00482378> (accessed 10 November 2014).
276. Song B, Wu Y, Yu M, Zhao P, Zhou C, Kiefer GE, Sherry AD. 2013 A europium(III)-based PARACEST agent for sensing singlet oxygen by MRI. *Dalton Trans.* **42**, 8066–8069. (doi:10.1039/C3DT50194A)
277. Tagaya M, Ikoma T, Xu Z, Tanaka J. 2014 Synthesis of luminescent nanoporous silica spheres functionalized with folic acid for targeting to cancer cells. *Inorg. Chem.* **53**, 6817–6827. (doi:10.1021/ic500609g)
278. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. 1999 Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. *Chem. Rev.* **99**, 2293–2352. (doi:10.1021/cr980440x)
279. Long-term retention of gadolinium in bone. See <https://clinicaltrials.gov/ct2/show/NCT01853163> (accessed 10 November 2014).
280. Chakraborty S, Unni PR, Banerjee S, Samuel G, Das T, Sarma HD, Ramamoorthy N, Pillai MRA. 2001 Potential ¹⁶⁶Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I: [¹⁶⁶Ho] holmium labeled ethylene dicysteine. *Nucl. Med. Biol.* **28**, 309–317. (doi:10.1016/S0969-8051(00)00197-9)
281. Suzuki YS, Momose Y, Higashi N, Shigematsu A, Park K-B, Kim YM, Kim JR, Ryu JM. 1998 Biodistribution and kinetics of holmium-166-chitosan complex (DW-166HC) in rats and mice. *J. Nucl. Med.* **39**, 2161–2166.
282. Vente MAD *et al.* 2009 Neutron activation of holmium poly(L-lactic acid) microspheres for hepatic arterial radioembolization: a validation study. *Biomed. Microdevices* **11**, 763–772. (doi:10.1007/s10544-009-9291-y)
283. Zielhuis SW, Nijssen JFW, de Roos R, Krijger GC, van Rijk PP, Hennink WE, van het Schip AD. 2006 Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application. *Int. J. Pharm.* **311**, 69–74. (doi:10.1016/j.ijpharm.2005.12.034)
284. Radioactive holmium microspheres for the treatment of liver metastases (HEPAR). See <https://clinicaltrials.gov/ct2/show/NCT01031784> (accessed 10 November 2014).
285. Radioactive holmium microspheres for the treatment of unresectable liver metastases (HEPAR 2). See <https://clinicaltrials.gov/ct2/show/NCT01612325> (accessed 10 November 2014).
286. Chakraborty S, Unni PR, Venkatesh M, Pillai MRA. 2002 Feasibility study for production of ¹⁷⁵Yb: a promising therapeutic radionuclide. *Appl. Radiat. Isot.* **57**, 295–301. (doi:10.1016/S0969-8043(02)00100-8)

287. Mathew B, Chakraborty S, Das T, Sarma HD, Banerjee S, Samuel G, Venkatesh M, Pillai MRA. 2004 ^{175}Yb labeled polyaminophosphonates as potential agents for bone pain palliation. *Appl. Radiat. Isot.* **60**, 635–642. (doi:10.1016/j.apradiso.2003.09.016)
288. Patel NS, Fan P, Chiu-Tsao S-T, Ravi K, Sherman W, Quon H, Pisch J, Tsao H-S, Harrison LB. 2001 Ytterbium-169: a promising new radionuclide for intravascular brachytherapy. *Cardiovasc. Radiat. Med.* **2**, 173–180. (doi:10.1016/S1522-1865(01)00085-3)
289. Liu Z *et al.* 2014 ^{177}Lu -labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. *Mol. Pharm.* **11**, 800–807. (doi:10.1021/mp4005047)
290. Shi W, Ogbomo SM, Wagh NK, Zhou Z, Jia Y, Brusnahan SK, Garrison JC. 2014 The influence of linker length on the properties of cathepsin S cleavable ^{177}Lu -labeled HPMA copolymers for pancreatic cancer imaging. *Biomaterials* **35**, 5760–5770. (doi:10.1016/j.biomaterials.2014.03.056)
291. TF2-small cell lung cancer radio immunotherapy. See <https://clinicaltrials.gov/ct2/show/NCT01221675> (accessed 10 November 2014).
292. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. 2003 Targeted actinium-225 in vivo generators for therapy of ovarian cancer. *Cancer Res.* **63**, 5084–5090.
293. Baidoo KE, Yong K, Brechbiel MW. 2013 Molecular pathways: targeted α -particle radiation therapy. *Clin. Cancer Res.* **19**, 530–537. (doi:10.1158/1078-0432.ccr-12-0298)
294. Low dose cytarabine and lintuzumab-Ac225 in older patients. See <https://clinicaltrials.gov/ct2/show/NCT01756677> (accessed 10 November 2014).
295. Targeted atomic nano-generators (actinium-225-labeled humanized anti-CD33 monoclonal antibody HuM195) in patients with advanced myeloid malignancies. See <https://clinicaltrials.gov/ct2/show/NCT00672165> (accessed 10 November 2014).
296. Dembitsky VM, Smoun R, Al-Quntar AAA, Ali HA, Pergament I, Srebnik M. 2002 Natural occurrence of boroncontaining compounds in plants, algae and microorganisms. *Plant Sci.* **163**, 931–942. (doi:10.1016/S0168-9452(02)00174-7)
297. Loomis WD, Durst RW. 1992 Chemistry and biology of boron. *BioFactors* **3**, 229–239.
298. Dinca L, Scorei R. 2013 Boron in human nutrition and its regulations use. *J. Nutr. Ther.* **2**, 22–29.
299. Newnham RE. 1994 Essentiality of boron for healthy bones and joints. *Environ. Health Perspect.* **102**, 83–85. (doi:10.1289/ehp.94102s783)
300. Price CT, Langford JR, Liporace FA. 2012 Essential nutrients for bone health and a review of their availability in the average North American diet. *Open Orthop. J.* **6**, 143–149. (doi:10.2174/1874325001206010143)
301. Pache W, Zähler H. 1969 Metabolic products of microorganisms. 77. Studies on the mechanism of action of boromycin. *Arch. Mikrobiol.* **67**, 156–165. (doi:10.1007/BF00409681)
302. Baker SJ, Tomsho JW, Benkovic SJ. 2011 Boron-containing inhibitors of synthetases. *Chem. Soc. Rev.* **40**, 4279–4285. (doi:10.1039/C0CS00131G)
303. Kohno J *et al.* 1996 Boromycin, an anti-HIV antibiotic. *Biosci. Biotechnol. Biochem.* **60**, 1036–1037. (doi:10.1271/bbb.60.1036)
304. Soriano-Ursúa MA, Das BC, Trujillo-Ferrara JG. 2014 Boron-containing compounds: chemico-biological properties and expanding medicinal potential in prevention, diagnosis and therapy. *Expert Opin. Ther. Pat.* **24**, 485–500. (doi:10.1517/13543776.2014.881472)
305. Sene S *et al.* 2014 A combined experimental-computational study of benzoxaborole crystal structures. *CrystEngComm* **16**, 4999–5011. (doi:10.1039/c4ce00313f)
306. Ciaravino V, Plattner J, Chanda S. 2013 An assessment of the genetic toxicology of novel boron-containing therapeutic agents. *Environ. Mol. Mutagen.* **54**, 338–346. (doi:10.1002/em.21779)
307. Kumar V, Gill KD. 2014 Oxidative stress and mitochondrial dysfunction in aluminium neurotoxicity and its amelioration: a review. *NeuroToxicology* **41**, 154–166. (doi:10.1016/j.neuro.2014.02.004)
308. Pineau A, Fauconneau B, Sappino A-P, Deloncle R, Guillard O. 2014 If exposure to aluminium in antiperspirants presents health risks, its content should be reduced. *J. Trace Elem. Med. Biol.* **28**, 147–150. (doi:10.1016/j.jtemb.2013.12.002)
309. Wills MR, Savory J. 1983 Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. *Lancet* **322**, 29–34. (doi:10.1016/S0140-6736(83)90014-4)
310. García A, De Sanctis JB. 2014 An overview of adjuvant formulations and delivery systems. *APMIS* **122**, 257–267. (doi:10.1111/apm.12143)

311. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. 2008 Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat. Immunol.* **9**, 847–856. (doi:10.1038/ni.1631)
312. Tomljenovic L, Shaw CA. 2011 Aluminum vaccine adjuvants: are they safe? *Curr. Med. Chem.* **18**, 2630–2637. (doi:10.2174/092986711795933740)
313. Malakoff D. 2000 Aluminum is put on trial as a vaccine booster. *Science* **288**, 1323–1324. (doi:10.1126/science.288.5470.1323)
314. Chitambar CR. 2010 Medical applications and toxicities of gallium compounds. *Int. J. Environ. Res. Public Health* **7**, 2337–2361. (doi:10.3390/ijerph7052337)
315. Lessa JA, Parrilha GL, Beraldo H. 2012 Gallium complexes as new promising metallodrug candidates. *Inorg. Chim. Acta* **393**, 53–63. (doi:10.1016/j.ica.2012.06.003)
316. Verron E, Boulter JM, Scimeca JC. 2012 Gallium as a potential candidate for treatment of osteoporosis. *Drug Discov. Today* **17**, 1127–1132. (doi:10.1016/j.drudis.2012.06.007)
317. Banerjee SR, Pomper MG. 2013 Clinical applications of gallium-68. *Appl. Radiat. Isot.* **76**, 2–13. (doi:10.1016/j.apradiso.2013.01.039)
318. Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A. 2009 Clinical indications for gallium-68 positron emission tomography imaging. *Eur. J. Surg. Oncol.* **35**, 561–567. (doi:10.1016/j.ejso.2009.01.007)
319. Gallium nitrate in treating children with brain tumor, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumors. See <https://clinicaltrials.gov/ct2/show/NCT00002543> (accessed 10 November 2014).
320. Nishiyama Y, Yamamoto Y, Toyama Y, Satoh K, Nagai M, Ohkawa M. 2003 Usefulness of ⁶⁷Ga scintigraphy in extranodal malignant lymphoma patients. *Ann. Nucl. Med.* **17**, 657–662. (doi:10.1007/BF02984971)
321. Gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma. See <https://clinicaltrials.gov/ct2/show/NCT00002578> (accessed 10 November 2014).
322. Phase II gallium nitrate in relapsed or refractory non-Hodgkin's lymphoma. See <https://clinicaltrials.gov/ct2/show/NCT00054808> (accessed 10 November 2014).
323. Warrell Jr RP, Coonley CJ, Straus DJ, Young CW. 1983 Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. *Cancer* **51**, 1982–1987. (doi:10.1002/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L)
324. Leyland-Jones B. 2004 Treating cancer-related hypercalcemia with gallium nitrate. *J. Support. Oncol.* **2**, 509–516.
325. Radiation therapy and gadolinium texaphyrin in treating patients with supratentorial glioblastoma multiforme. See <https://clinicaltrials.gov/ct2/show/NCT00004262> (accessed 10 November 2014).
326. Hoffman LR, Ramsey BW. 2013 Cystic fibrosis therapeutics: the road ahead. *Chest* **143**, 207–213. (doi:10.1378/chest.12-1639)
327. 111 indium CHX-A DTPA trastuzumab (indium-herceptin) for imaging breast cancer. See <https://clinicaltrials.gov/ct2/show/NCT01445054> (accessed 10 November 2014).
328. Yttrium Y 90 ibritumomab tiuxetan, rituximab, indium In-111 ibritumomab tiuxetan, fludarabine, melphalan, and donor stem cell transplant in treating patients with B-cell non-Hodgkin lymphoma. See <https://clinicaltrials.gov/ct2/show/study/NCT00577278> (accessed 10 November 2014).
329. Romao CC, Blattler WA, Seixas JD, Bernardes GJL. 2012 Developing drug molecules for therapy with carbon monoxide. *Chem. Soc. Rev.* **41**, 3571–3583. (doi:10.1039/C2CS15317C)
330. Johnson TR, Mann BE, Clark JE, Foresti R, Green CJ, Motterlini R. 2003 Metal carbonyls: a new class of pharmaceuticals? *Angew. Chem. Int. Ed. Engl.* **42**, 3722–3729. (doi:10.1002/anie.200301634)
331. Mann BE, Motterlini R. 2007 CO and NO in medicine. *Chem. Commun.* 4197–4208. (doi:10.1039/B704873D)
332. Martin KR. 2013 Silicon: the health benefits of a metalloid. In *Interrelations between essential metal ions and human diseases* (eds RKO Sigel, A Sigel, H Sigel), pp. 451–473. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
333. Jugdaohsingh R. 2007 Silicon and bone health. *J. Nutr. Health Aging* **11**, 99–110.
334. Price CT, Koval KJ, Langford JR. 2013 Silicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosis. *Int. J. Endocrinol.* **2013**, 316783. (doi:10.1155/2013/316783)

335. Ahmad N, Gupta S, Feyes DK, Muktar H. 2000 Involvement of Fas (APO-1/CD-95) during photodynamic-therapy-mediated apoptosis in human epidermoid carcinoma A431 cells. *J. Invest. Dermatol.* **115**, 1041–1046. (doi:10.1046/j.1523-1747.2000.00147.x)
336. Ke MS *et al.* 2008 Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. *Photochem. Photobiol.* **84**, 407–414. (doi:10.1111/j.1751-1097.2007.00278.x)
337. Baron ED *et al.* 2010 Silicon phthalocyanine (pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. *Lasers Surg. Med.* **42**, 888–895. (doi:10.1002/lsm.20984)
338. Lee TK, Baron ED, Foster TH. 2008 Monitoring Pc 4 photodynamic therapy in clinical trials of cutaneous T-cell lymphoma using noninvasive spectroscopy. *J. Biomed. Opt.* **13**, 030507. (doi:10.1117/1.2939068)
339. Photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides. See <https://clinicaltrials.gov/ct2/show/NCT00103246> (accessed 10 November 2014).
340. Silicon phthalocyanine 4 and photodynamic therapy in stage IA-IIA cutaneous T-cell non-Hodgkin lymphoma. See <https://clinicaltrials.gov/ct2/show/NCT01800838> (accessed 10 November 2014).
341. Sabbioni E, Fortaner S, Bosisio S, Farina M, Del Torchio R, Edel J, Fischbach M. 2010 Metabolic fate of ultratrace levels of GeCl₄ in the rat and *in vitro* studies on its basal cytotoxicity and carcinogenic potential in Balb/3T3 and HaCaT cell lines. *J. Appl. Toxicol.* **30**, 34–41. (doi:10.1002/jat.1469)
342. Tao SH, Bolger PM. 1997 Hazard assessment of germanium supplements. *Regul. Toxicol. Pharmacol.* **25**, 211–219. (doi:10.1006/rtp.1997.1098)
343. Schauss AG. 1991 Nephrotoxicity in humans by the ultratrace element germanium. *Ren. Fail.* **13**, 1–4. (doi:10.3109/08860229109022139)
344. Gerber GB, Léonard A. 1997 Mutagenicity, carcinogenicity and teratogenicity of germanium compounds. *Mutat. Res.* **387**, 141–146. (doi:10.1016/S1383-5742(97)00034-3)
345. Gerik S, Maypole J. 2008 Overview of biologically based therapies in rehabilitation. In *Complementary therapies for physical therapy* (eds JE Deutsch, EZ Anderson), pp. 156–175. Saint Louis, MO: W.B. Saunders.
346. Menchikov LG, Ignatenko MA. 2013 Biological activity of organogermanium compounds (a review). *Pharm. Chem. J.* **46**, 635–638. (doi:10.1007/s11094-013-0860-2)
347. Allison RR, Sibata CH. 2010 Oncologic photodynamic therapy photosensitizers: a clinical review. *Photodiagnosis Photodyn. Ther.* **7**, 61–75. (doi:10.1016/j.pdpdt.2010.02.001)
348. Alama A, Tasso B, Novelli F, Sparatore F. 2009 Organometallic compounds in oncology: implications of novel organotin as antitumor agents. *Drug Discov. Today* **14**, 500–508. (doi:10.1016/j.drudis.2009.02.002)
349. Kovala-Demertzi D. 2006 Recent advances on non-steroidal anti-inflammatory drugs, NSAIDs: organotin complexes of NSAIDs. *J. Organomet. Chem.* **691**, 1767–1774. (doi:10.1016/j.jorganchem.2005.11.058)
350. Hadjidakou SK, Hadjiliadis N. 2009 Antiproliferative and anti-tumor activity of organotin compounds. *Coord. Chem. Rev.* **253**, 235–249. (doi:10.1016/j.ccr.2007.12.026)
351. Basu B, Tushar S. 2008 Antimicrobial activity of organotin(IV) compounds: a review. *Appl. Organomet. Chem.* **22**, 195–204. (doi:10.1002/aoc.1378)
352. Nath M. 2008 Toxicity and the cardiovascular activity of organotin compounds: a review. *Appl. Organomet. Chem.* **22**, 598–612. (doi:10.1002/aoc.1436)
353. Tiwari S, Tripathi IP, Tiwari HL. 2013 Lead poisoning—a review. *Res. J. Chem. Sci.* **3**, 86–88.
354. Goyer RA. 1993 Lead toxicity: current concerns. *Environ. Health Perspect.* **100**, 177–187. (doi:10.1289/ehp.93100177)
355. Flora G, Gupta D, Tiwari A. 2012 Toxicity of lead: a review with recent updates. *Interdiscip. Toxicol.* **5**, 47–58. (doi:10.2478/v10102-012-0009-2)
356. Patrick L. 2006 Lead toxicity, a review of the literature. Part 1: exposure, evaluation, and treatment. *Altern. Med. Rev.* **11**, 2–22.
357. Meredith RF *et al.* 2014 Pharmacokinetics and imaging of ²¹²Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. *Cancer Biother. Radiopharm.* **29**, 12–17. (doi:10.1089/cbr.2013.1531)

358. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 2013 ^{212}Pb -radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. *Br. J. Cancer* **108**, 2013–2020. (doi:10.1038/bjc.2013.189)
359. Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, Rixe O, Spitz HB, Dong Z. 2012 Significant systemic therapeutic effects of high-LET immunoradiation by ^{212}Pb -trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. *Int. J. Oncol.* **40**, 1881–1888. (doi:10.3892/ijo.2012.1357)
360. Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Flynn J, Brechbiel MW. 2008 Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. *Clin. Cancer Res.* **14**, 5108–5115. (doi:10.1158/1078-0432.CCR-08-0256)
361. Farrugia G, Szurszewski JH. 2014 Carbon monoxide, hydrogen sulfide, and nitric oxide as signaling molecules in the gastrointestinal tract. *Gastroenterology* **147**, 303–313. (doi:10.1053/j.gastro.2014.04.041)
362. Röszer T. 2012 *The biology of subcellular nitric oxide*, pp. 3–16. Dordrecht, The Netherlands: Springer.
363. Knowles RG, Moncada S. 1994 Nitric oxide synthases in mammals. *Biochem. J.* **298**, 249–258.
364. Harper PV *et al.* 1973 Clinical myocardial imaging with nitrogen-13 ammonia. *Radiology* **108**, 613–617. (doi:10.1148/108.3.613)
365. Machac J. 2007 Radiopharmaceuticals for clinical cardiac PET imaging. In *Cardiac PET and PET/CT imaging* (eds MF Di Carli, MJ Lipton), pp. 73–82. New York, NY: Springer.
366. Baker SB, Worthley LI. 2002 The essentials of calcium, magnesium and phosphate metabolism: part I. *Physiology. Crit. Care Resusc.* **4**, 301–306.
367. Amanzadeh J, Reilly RF. 2006 Hypophosphatemia: an evidence-based approach to its clinical consequences and management. *Nat. Clin. Pract. Nephrol.* **2**, 136–148. (doi:10.1038/ncpneph0124)
368. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. 2008 Hyperphosphatemia of chronic kidney disease. *Kidney Int.* **74**, 148–157. (doi:10.1038/ki.2008.130)
369. Woolfenden JM, Barber HB. 1989 Radiation detector probes for tumor localization using tumor-seeking radioactive tracers. *Am. J. Roentgenol.* **153**, 35–39. (doi:10.2214/ajr.153.1.35)
370. Wilcox DE. 2013 Arsenic. Can this toxic metalloid sustain life? In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 475–498. Dordrecht, The Netherlands: Springer.
371. Naujokas ME, Anderson B, Ahsan H, Aposhian HV, Graziano JH, Thompson C, Suk WA. 2013 The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. *Environ. Health Perspect.* **121**, 295–302. (doi:10.1289/ehp.1205875)
372. Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M. 2007 Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. *Exp. Biol. Med.* **232**, 3–13.
373. Samikkannu T, Chen C-H, Yih L-H, Wang ASS, Lin S-Y, Chen T-C, Jan K-Y. 2003 Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity. *Chem. Res. Toxicol.* **16**, 409–414. (doi:10.1021/tx025615j)
374. Antman KH. 2001 Introduction: the history of arsenic trioxide in cancer therapy. *Oncologist* **6**, 1–2. (doi:10.1634/theoncologist.6-suppl_2-1)
375. Jaouen G, Beck W, McGlinchey MJ. 2006 A novel field of research: bioorganometallic chemistry, origins, and founding principles. In *Bioorganometallics: biomolecules, labeling, medicine* (ed. G Jaouen), pp. 1–37. Weinheim, Germany: Wiley-VCH.
376. Blower PJ. 2004 30 Inorganic pharmaceuticals. *Annu. Rep. Prog. Chem. Sect. A* **100**, 633–658. (doi:10.1039/B312109G)
377. Fang J, Chen S-J, Tong J-H, Wang Z-G, Chen G-Q, Chen Z. 2002 Treatment of acute promyelocytic leukemia with ATRA and As_2O_3 . *Cancer Biol. Ther.* **1**, 614–620. (doi:10.4161/cbt.308)
378. Icotinib and arsenic trioxide in treating non-small-cell lung cancer patients with resistance to EGFR-TKI. See <https://clinicaltrials.gov/ct2/show/NCT02066870> (accessed 10 November 2014).
379. Arsenic trioxide TACE and intravenous administration in unresectable hepatocellular carcinoma (ACTION). See <https://clinicaltrials.gov/ct2/show/NCT01861912> (accessed 10 November 2014).

380. Bisser S, N'Siesi F-X, Lejon V, Preux P-M, Van Nieuwenhove S, Miaka Mia Bilenge C, Büscher P. 2007 Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage *Trypanosoma brucei* gambiense sleeping sickness. *J. Infect. Dis.* **195**, 322–329. (doi:10.1086/510534)
381. Tsimberidou AM *et al.* 2009 A phase I clinical trial of darinaparsin in patients with refractory solid tumors. *Clin. Cancer Res.* **15**, 4769–4776. (doi:10.1158/1078-0432.CCR-08-2984)
382. Wu J *et al.* 2010 Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. *Invest. New Drugs* **28**, 670–676. (doi:10.1007/s10637-009-9286-9)
383. Garnier N *et al.* 2014 The novel arsenical darinaparsin is transported by cystine importing systems. *Mol. Pharmacol.* **85**, 576–585. (doi:10.1124/mol.113.089433)
384. Frézard F, Demicheli C, Ribeiro RR. 2009 Pentavalent antimonials: new perspectives for old drugs. *Molecules* **14**, 2317–2336. (doi:10.3390/molecules14072317)
385. Halder AK, Sen P, Roy S. 2011 Use of antimony in the treatment of leishmaniasis: current status and future directions. *Mol. Biol. Int.* **2011**, 571242. (doi:10.4061/2011/571242)
386. Nühs A *et al.* 2013 A novel marker, ARM58, confers antimony resistance to *Leishmania* spp. *Int. J. Parasitol. Drugs Drug Resist.* **4**, 37–47. (doi:10.1016/j.ijpddr.2013.11.004)
387. Yan S, Wong ILK, Chow LMC, Sun H. 2003 Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation. *Chem. Commun.* 266–267. (doi:10.1039/B210240D)
388. Yan S, Li F, Ding K, Sun H. 2003 Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione. *J. Biol. Inorg. Chem.* **8**, 689–697. (doi:10.1007/s00775-003-0468-1)
389. Baiocco P, Colotti G, Franceschini S, Ilari A. 2009 Molecular basis of antimony treatment in leishmaniasis. *J. Med. Chem.* **52**, 2603–2612. (doi:10.1021/jm900185q)
390. Sundar S, Chakravarty J. 2010 Antimony toxicity. *Int. J. Environ. Res. Public Health* **7**, 4267–4277. (doi:10.3390/ijerph7124267)
391. Thomas F, Bialek B, Hensel R. 2011 Medical use of bismuth: the two sides of the coin. *J. Clin. Toxicol.* S3:004. (doi:10.4172/2161-0495.S3-004)
392. Sun H, Li H, Sadler PJ. 1997 The biological and medicinal chemistry of bismuth. *Chem. Ber.* **130**, 669–681. (doi:10.1002/cber.19971300602)
393. Sadler PJ, Li H, Sun H. 1999 Coordination chemistry of metals in medicine: target sites for bismuth. *Coord. Chem. Rev.* **185–186**, 689–709. (doi:10.1016/S0010-8545(99)00018-1)
394. Mai L-M, Lin C-Y, Chen C-Y, Tsai Y-C. 2003 Synergistic effect of bismuth subgallate and borneol, the major components of Sulbogin[®], on the healing of skin wound. *Biomaterials* **24**, 3005–3012. (doi:10.1016/S0142-9612(03)00126-1)
395. Thorisdottir H, Ratnoff OD, Maniglia AJ. 1988 Activation of Hageman factor (factor XII) by bismuth subgallate, a hemostatic agent. *J. Lab. Clin. Med.* **112**, 481–486.
396. Yang N, Sun H. 2007 Biocoordination chemistry of bismuth: recent advances. *Coord. Chem. Rev.* **251**, 2354–2366. (doi:10.1016/j.ccr.2007.03.003)
397. Tiekink ERT. 2002 Antimony and bismuth compounds in oncology. *Crit. Rev. Oncol. Hematol.* **42**, 217–224. (doi:10.1016/S1040-8428(01)00217-7)
398. Jurcic JG *et al.* 2002 Targeted alpha particle immunotherapy for myeloid leukemia. *Blood* **100**, 1233–1239.
399. Rosenblatt TL *et al.* 2010 Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. *Clin. Cancer Res.* **16**, 5303–5311. (doi:10.1158/1078-0432.CCR-10-0382)
400. Michiels C. 2004 Physiological and pathological responses to hypoxia. *Am. J. Pathol.* **164**, 1875–1882. (doi:10.1016/S0002-9440(10)63747-9)
401. Ward JPT. 2008 Oxygen sensors in context. *Biochim. Biophys. Acta* **1777**, 1–14. (doi:10.1016/j.bbabi.2007.10.010)
402. Mach WJ, Thimmesch AR, Pierce JT, Pierce JD. 2011 Consequences of hyperoxia and the toxicity of oxygen in the lung. *Nurs. Res. Pract.* **2011**, 260482. (doi:10.1155/2011/260482)
403. Forman HJ, Maiorino M, Ursini F. 2010 Signaling functions of reactive oxygen species. *Biochemistry* **49**, 835–842. (doi:10.1021/bi9020378)
404. Rabinowitz MH. 2013 Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. *J. Med. Chem.* **56**, 9369–9402. (doi:10.1021/jm400386j)
405. Ingenbleek Y, Kimura H. 2013 Nutritional essentiality of sulfur in health and disease. *Nutr. Rev.* **71**, 413–432. (doi:10.1111/nure.12050)

406. Pompella A, Visvikis A, Paolicchi A, Tata VD, Casini AF. 2003 The changing faces of glutathione, a cellular protagonist. *Biochem. Pharmacol.* **66**, 1499–1503. (doi:10.1016/S0006-2952(03)00504-5)
407. Wollman EE *et al.* 1988 Cloning and expression of a cDNA for human thioredoxin. *J. Biol. Chem.* **263**, 15 506–15 512.
408. Paul BD, Snyder SH. 2012 H₂S signalling through protein sulfhydration and beyond. *Nat. Rev. Mol. Cell Biol.* **13**, 499–507. (doi:10.1038/nrm3391)
409. Mustafa AK *et al.* 2009 H₂S signals through protein S-sulfhydration. *Sci. Signal.* **2**, ra72. (doi:10.1126/scisignal.2000464)
410. Li L, Rose P, Moore PK. 2011 Hydrogen sulfide and cell signaling. *Annu. Rev. Pharmacol. Toxicol.* **51**, 169–187. (doi:10.1146/annurev-pharmtox-010510-100505)
411. Hausenloy DJ, Yellon DM. 2009 Preconditioning and postconditioning: underlying mechanisms and clinical application. *Atherosclerosis* **204**, 334–341. (doi:10.1016/j.atherosclerosis.2008.10.029)
412. Mani S *et al.* 2013 Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. *Circulation* **127**, 2523–2534. (doi:10.1161/CIRCULATIONAHA.113.002208)
413. Xu S, Liu Z, Liu P. 2014 Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis. *Int. J. Cardiol.* **172**, 313–317. (doi:10.1016/j.ijcard.2014.01.068)
414. Kurokawa S, Berry MJ. 2013 Selenium. Role of the essential metalloid in health. In *Interrelations between essential metal ions and human diseases* (eds A Sigel, H Sigel, RKO Sigel), pp. 499–534. Dordrecht, The Netherlands: Springer Science and Business Media B.V.
415. Se-Methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. See <https://clinicaltrials.gov/ct2/show/NCT01497431>.
416. Parish L, Parish J, Routh H. 2008 Selenium sulfide in the 21st century. *J. Am. Acad. Dermatol.* **58**, AB72. (doi:10.1016/j.jaad.2007.10.319)
417. Cunha RLOR, Gouveia IE, Juliano L. 2009 A glimpse on biological activities of tellurium compounds. *An. Acad. Bras. Cienc.* **81**, 393–407. (doi:10.1590/S0001-37652009000300006)
418. Sredni B, Albeck M, Tichler T, Shani A, Shapira J, Bruderman I, Catane R, Kaufman B, Kalechman Y. 1995 Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. *J. Clin. Oncol.* **13**, 2342–2353.
419. Patients, safety and efficacy study of AS101 to treat elderly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). See <https://clinicaltrials.gov/ct2/show/NCT01010373>.
420. Safety and efficacy double blind vehicle controlled study of 15% AS101 gel to treat external genital warts. See <https://clinicaltrials.gov/ct2/show/NCT01943630>.
421. Halpert G, Eitan T, Voronov E, Apte RN, Rath-Wolfson L, Albeck M, Kalechman Y, Sredni B. 2014 Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis. *J. Biol. Chem.* **289**, 17 215–17 227. (doi:10.1074/jbc.M113.536664)
422. Rocha RA, Devesa V, Vélez D. 2013 In vitro study of intestinal transport of fluoride using the Caco-2 cell line. *Food Chem. Toxicol.* **55**, 146–163. (doi:10.1016/j.fct.2012.12.037)
423. Mohapatra M, Anand S, Mishra BK, Giles DE, Singh P. 2009 Review of fluoride removal from drinking water. *J. Environ. Manage.* **91**, 67–77. (doi:10.1016/j.jenvman.2009.08.015)
424. Everett ET. 2011 Fluoride's effects on the formation of teeth and bones, and the influence of genetics. *J. Dent. Res.* **90**, 552–560. (doi:10.1177/0022034510384626)
425. Buzalaf MAR, Whitford GM. 2011 Fluoride metabolism. In *Fluoride and the oral environment* (ed. MAR Buzalaf), pp. 20–36. Basel, Switzerland: Karger.
426. Li L. 2003 The biochemistry and physiology of metallic fluoride: action, mechanism, and implications. *Crit. Rev. Oral Biol. Med.* **14**, 100–114. (doi:10.1177/154411130301400204)
427. Strunecká A, Patoëka J, Connett P. 2004 Fluorine in medicine. *J. Appl. Biomed.* **2**, 141–150.
428. Filler R, Saha R. 2009 Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. *Future Med. Chem.* **1**, 777–791. (doi:10.4155/fmc.09.65)
429. Bhatnagar A, Hustinx R, Alavi A. 2000 Nuclear imaging methods for non-invasive drug monitoring. *Adv. Drug Deliv. Rev.* **41**, 41–54. (doi:10.1016/S0169-409X(99)00055-1)
430. Schirmer M, Calamia KT, Wenger M, Klauser A, Salvarani C, Moncayo R. 2003 ¹⁸F-Fluorodeoxyglucose-positron emission tomography: a new explorative perspective. *Exp. Gerontol.* **38**, 463–470. (doi:10.1016/S0531-5565(02)00267-X)

431. Akabas MH. 2000 Cystic fibrosis transmembrane conductance regulator: structure and function of an epithelial chloride channel. *J. Biol. Chem.* **275**, 3729–3732. (doi:10.1074/jbc.275.6.3729)
432. Wine JJ. 1999 The genesis of cystic fibrosis lung disease. *J. Clin. Invest.* **103**, 309–312. (doi:10.1172/JCI6222)
433. Pilewski JM, Frizzell RA. 1999 Role of CFTR in airway disease. *Physiol. Rev.* **79**, S215–S255.
434. De Braekeleer M, Férec C. 1996 Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. *Mol. Hum. Reprod.* **2**, 669–677. (doi:10.1093/molehr/2.9.669)
435. Kettle AJ, Albrett AM, Chapman AL, Dickerhof N, Forbes LV, Khalilova I, Turner R. 2014 Measuring chlorine bleach in biology and medicine. *Biochim. Biophys. Acta* **1840**, 781–793. (doi:10.1016/j.bbagen.2013.07.004)
436. Kettle AJ, Anderson RF, Hampton MB, Winterbourn CC. 2007 Reactions of superoxide with myeloperoxidase. *Biochemistry* **46**, 4888–4897. (doi:10.1021/bi602587k)
437. Aldridge RE, Chan T, van Dalen CJ, Senthilmohan R, Winn M, Venge P, Town GI, Kettle AJ. 2002 Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. *Free Radic. Biol. Med.* **33**, 847–856. (doi:10.1016/S0891-5849(02)00976-0)
438. Mayeno AN, Curran AJ, Roberts RL, Foote CS. 1989 Eosinophils preferentially use bromide to generate halogenating agents. *J. Biol. Chem.* **264**, 5660–5668.
439. McCall AS, Cummings CF, Bhave G, Vanacore R, Page-McCaw A, Hudson BG. 2014 Bromine is an essential trace element for assembly of collagen IV scaffolds in tissue development and architecture. *Cell* **157**, 1380–1392. (doi:10.1016/j.cell.2014.05.009)
440. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. 2003 The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. *Endocr. Rev.* **24**, 48–77. (doi:10.1210/er.2001-0029)
441. Carrasco N. 1993 Iodide transport in the thyroid gland. *Biochim. Biophys. Acta* **1154**, 65–82. (doi:10.1016/0304-4157(93)90017-I)
442. Mazzaferri EL. 2000 Carcinoma of the follicular epithelium. In *The thyroid: a fundamental and clinical text*, 8th edn (eds LE Braverman, R Utiger), pp. 904–930. Philadelphia, PA: Lippincott.
443. Cho JY, Xing S, Liu X, Buckwalter TL, Hwa L, Sferra TJ, Chiu IM, Jhiang SM. 2000 Expression and activity of human Na/I symporter in human glioma cells by adenovirus-mediated gene delivery. *Gene Ther.* **7**, 740–749. (doi:10.1038/sj.gt.3301170)
444. Tazebay UH *et al.* 2000 The mammary gland iodide transporter is expressed during lactation and in breast cancer. *Nat. Med.* **6**, 871–878. (doi:10.1038/78630)
445. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. 2008 Clinical experience with α -particle-emitting ^{211}At : treatment of recurrent brain tumor patients with ^{211}At -labeled chimeric antitenascin monoclonal antibody 81C6. *J. Nucl. Med.* **49**, 30–38. (doi:10.2967/jnumed.107.046938)
446. Andersson H *et al.* 2009 Intraperitoneal α -particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of ^{211}At -MX35 F(ab')₂—a phase I study. *J. Nucl. Med.* **50**, 1153–1160. (doi:10.2967/jnumed.109.062604)
447. Berganza CJ, Zhang JH. 2013 The role of helium gas in medicine. *Med. Gas Res.* **3**, 18. (doi:10.1186/2045-9912-3-18)
448. Makarov DV, Daraspreet K, Link RE, Kavoussi LR. 2007 Physiologic changes during helium insufflation in high-risk patients during laparoscopic renal procedures. *Urology* **70**, 35–37. (doi:10.1016/j.urology.2007.03.010)
449. Rice WL, Van Hoek AN, Păunescu TG, Huynh C, Goetze B, Singh B, Scipioni L, Stern LA, Brown D. 2013 High resolution helium ion scanning microscopy of the rat kidney. *PLoS One* **8**, e57051. (doi:10.1371/journal.pone.0057051)
450. Raiser J, Zenker M. 2006 Argon plasma coagulation for open surgical and endoscopic applications: state of the art. *J. Phys. D Appl. Phys.* **39**, 3520–3523. (doi:10.1088/0022-3727/39/16/S10)
451. Farin G, Grund KE. 1994 Technology of argon plasma coagulation with particular regard to endoscopic applications. *Endosc. Surg. Allied Technol.* **2**, 71–77.
452. Grund KE, Storek D, Farin G. 1994 Endoscopic argon plasma coagulation (APC): first clinical experiences in flexible endoscopy. *Endosc. Surg. Allied Technol.* **2**, 42–46.
453. Pavlovskaya GE, Cleveland ZI, Stupic KF, Basaraba RJ, Meersmann T. 2005 Hyperpolarized krypton-83 as a contrast agent for magnetic resonance imaging. *Proc. Natl Acad. Sci. USA* **102**, 18 275–18 279. (doi:10.1073/pnas.0509419102)

454. Cleveland ZI, Pavlovskaya GE, Elkins ND, Stupic KF, Repine JE, Meersmann T. 2008 Hyperpolarized ^{83}Kr MRI of lungs. *J. Magn. Reson.* **195**, 232–237. (doi:10.1016/j.jmr.2008.09.020)
455. Harris K, Armstrong SP, Campos-Pires R, Kiru L, Franks NP, Dickinson R. 2013 Neuroprotection against traumatic brain injury by xenon, but not argon, is mediated by inhibition at the N-methyl-d-aspartate receptor glycine site. *Anesthesiology* **119**, 1137–1148. (doi:10.1097/ALN.0b013e3182a2a265)
456. Esencan E, Yuksel S, Tosun YB, Robinot A, Solaroglu I, Zhang JH. 2013 Xenon in medical area: emphasis on neuroprotection in hypoxia and anesthesia. *Med. Gas Res.* **3**, 4. (doi:10.1186/2045-9912-3-4)
457. Suga K. 2002 Technical and analytical advances in pulmonary ventilation SPECT with xenon-133 gas and Tc-99m-Technegas. *Ann. Nucl. Med.* **16**, 303–310. (doi:10.1007/bf02988614)
458. Henriksen OM, Kruuse C, Olesen J, Jensen LT, Larsson HB, Birk S, Hansen JM, Wienecke T, Rostrup E. 2013 Sources of variability of resting cerebral blood flow in healthy subjects: a study using ^{133}Xe SPECT measurements. *J. Cereb. Blood Flow Metab.* **33**, 787–792. (doi:10.1038/jcbfm.2013.17)
459. Albert MS, Balamore D. 1998 Development of hyperpolarized noble gas MRI. *Nucl. Instrum. Methods Phys. Res. A* **402**, 441–453. (doi:10.1016/S0168-9002(97)00888-7)
460. Ojo TJ, Ajayi IR. 2014 A review on environmental radon and its potential health risk on humans. *J. Environ. Sci. Toxicol. Food Technol.* **8**, 1–8. (doi:10.9790/2402-08140108)
461. Truta LA, Hofmann W, Cosma C. 2014 Lung cancer risk due to residential radon exposures: estimation and prevention. *Radiat. Prot. Dosimetry* **160**, 112–116. (doi:10.1093/rpd/ncu062)
462. Williams RJ. 1997 The natural selection of the chemical elements. *Cell. Mol. Life Sci.* **53**, 816–829. (doi:10.1007/s000180050102)
463. Williams RJP, Fraústo da Silva JJR. 1997 *The natural selection of the chemical elements, the environment and life's chemistry*. Oxford, UK: Clarendon Press.
464. Williams RJP, Rickaby R. 2012 *Evolution's destiny: co-evolving chemistry of the environment and life*. Cambridge, UK: Royal Society of Chemistry.
465. Bianco AC, Kim BW. 2006 Deiodinases: implications of the local control of thyroid hormone action. *J. Clin. Invest.* **116**, 2571–2579. (doi:10.1172/JCI29812)
466. Takahashi N, Ortel TL, Putnam FW. 1984 Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule. *Proc. Natl Acad. Sci. USA* **81**, 390–394. (doi:10.1073/pnas.81.2.390)
467. Yu W, Foster HD, Zhang T. 1995 Discovering Chinese mineral drugs. *J. Orthomol. Med.* **10**, 31–58.